NEW YORK, NY–(Marketwire – August 19, 2010) –  Allied Healthcare International Inc. (NASDAQ: AHCI) (AIM: AHI), a leading provider of flexible healthcare staffing services in the United Kingdom, announced today that G. Richard Green has tendered his resignation as a member of the Company’s Board of Directors for personal reasons, effective August 21, 2010. Mr. Green has been a director of Allied since 1998 and recently served on the Nominating and Corporate Governance Committee of the Board.

The Company also announced that Professor Raymond John Playford has been appointed to the Board of Directors of Allied, effective August 21, 2010. Prof. Playford, age 50, has served as Medical Advisor to the Board of Allied since June 2010.

Dr. Jeffrey S. Peris, Chairman of the Board of Allied Healthcare International Inc., commented, “Richard has served with distinction on our Board. His intellect, depth of business knowledge and leadership experience have contributed greatly to Allied’s growth and success throughout his long tenure as our director. On behalf of the entire Board, senior management team and employees of Allied, we want to wish Richard years of health and happiness.”

Dr. Peris also stated, “Ray has already made many valuable contributions since he joined us as Medical Advisor, and we welcome him to the Board to further assist us in augmenting the growth strategies of our Company. His wealth of clinical, healthcare and NHS expertise will both support our commitment to providing our customers with one of the highest levels of quality care in our industry and to enhancing the market leadership of Allied.”

Prof. Playford has more than 25 years of experience in the medical field, specializing in clinical research. He is currently Deputy Warden and Professor of Medicine at Barts and the London School of Medicine and Dentistry, as well as Vice Principal (NHS Liaison), Queen Mary, University of London. Prof. Playford is also a Non-Executive Director of Barking, Havering and Redbridge NHS Trust and a director of Repair and Protection Foods Ltd., which is engaged in food research. He has also been an advisor to both the UK Government and the healthcare industry.

Prof. Playford received a Medical degree (M.B., B.S.) in 1978 from St. Bartholomew’s Medical School and his PhD in 1992 from the Royal Postgraduate Medical School at Imperial College, London. He is a Fellow of the Royal College of Physicians (UK) and the Royal College of Pathologists (UK) and was Visiting Professor, Harvard Medical School and Massachusetts General Hospital in 2002. He has published over 100 original scientific and clinical papers and received several awards for research including the British Society of Gastroenterology (BSG) Sir Francis Avery Jones Research Medal in 1995 and Canadian Alberta Heritage Foundation for Medical Research in 2004. He was made a Fellow of the Academy of Medical Scientists in 2002 and, as a result of his contribution to public education on health matters, became a Fellow of the Royal Society of Arts in 2000.

There are no further disclosures regarding Prof. Playford that are required to be set forth in this press release under the AIM rules.

About Allied Healthcare International Inc.

Allied Healthcare International Inc. is a leading provider of flexible healthcare staffing services in the United Kingdom. Allied operates a community-based network of approximately 115 branches with the capacity to provide carers (known as home health aides in the U.S.), nurses, and specialized medical personnel to locations covering approximately 90% of the U.K. population. Allied meets the needs of private patients, community care, nursing and care homes, and hospitals. For more news and information please visit: www.alliedhealthcare.com.

Forward-Looking Statements

Certain statements contained in this news release may be forward-looking statements. These forward-looking statements are based on current expectations and projections about future events. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ from those implied by the forward-looking statements include: general economic and market conditions; the effect of the change in the U.K. government and the impact of proposed changes in recent policy making related to health and social care that may reduce revenue and profitability; Allied’s ability to continue to recruit and retain flexible healthcare staff; Allied’s ability to enter into contracts with local government social services departments, NHS Trusts, hospitals, other healthcare facility clients and private clients on terms attractive to Allied; the general level of demand for healthcare and social care; dependence on the proper functioning of Allied’s information systems; the effect of existing or future government regulation of the healthcare and social care industry, and Allied’s ability to comply with these regulations; the impact of medical malpractice and other claims asserted against Allied; the effect of regulatory change that may apply to Allied and that may increase costs and reduce revenues and profitability; Allied’s ability to use net operating loss carry forwards to offset net income; the effect that fluctuations in foreign currency exchange rates may have on our dollar-denominated results of operations; and the impairment of goodwill, of which Allied has a substantial amount on the balance sheet, may have the effect of decreasing earnings or increasing losses. Other factors that could cause actual results to differ from those implied by the forward-looking statements in this press release include those described in Allied’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. Allied undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 

POMONA, CA–(Marketwire – August 18, 2010) –  Western University of Health Sciences has surpassed its Capital Campaign goal of $35 million, but the work is far from over.

“We are very grateful for the support we have received for the Capital Campaign and, by extension, for our goal of building one of the most comprehensive academic health science centers in the nation,” said WesternU President Philip Pumerantz, PhD. “We also know that we must continue to build partnerships and raise awareness of our innovative programs, world-class facilities and skilled faculty and students.”

The Capital Campaign had a six-year goal of raising $35 million by WesternU’s 35^th anniversary in 2012, which was reached with two years to spare. The campaign has raised $36.5 million from about 1,600 donors as of July 2010. About $27 million has already been received, with the balance pledges to be paid before June 2012.

“This is real money that is in,” said Thomas Fox, PhD, Senior Vice President for Advancement. “Now we’ll see how far we can go.”

The Capital Campaign Case Statement set fundraising goals for specific categories, including $12.5 million for infrastructure, $8.75 million for student support and $7 million for faculty support. In the next two years, University Advancement will continue to raise money and ensure fundraising goals for each category are met, Fox said.

“Student scholarships are important. As we continue to emerge as a research organization, faculty support will be important,” he said. “With the Patient Care Center, health care strategy is another one we will look for as well.”

The Capital Campaign has reached out to new donors large and small. The $100 million campus expansion has helped raise interest in the Capital Campaign and provides many naming opportunities. The start of four new colleges in the past year allowed WesternU to tap into new prospects, Fox said.

“It is important to add donors,” he said. “We’re adding people who have never given to the university before. The message is getting out there.”

TULSA, OK–(Marketwire – August 18, 2010) –  MacroSolve, Inc. (OTCBB: MCVE), a leading provider of mobile business solutions, announced today that its patent-pending ReForm XT™, has been selected by Orthopedic Resources, a growing medical products distributor, for its wireless inventory and order tracking platform. 

Tulsa, Oklahoma-based Orthopedic Resources is a rapidly growing distributor of Durable Medical Equipment. The company has more than 50 national and regional insurance contracts and services the southwestern and mid-western United States.

Mark Farrow, President of Orthopedic Resources, commented, “In order to support the tremendous growth in sales we’ve experienced, we decided it was time for us to move from mainly paper-based inventory and order systems to a mobile solution. ReForm XT is the right product for us. It will help our growing sales force of over 50 people provide superior service to the 250-plus hospitals we serve. ReForm XT will help us meet our goals to automate, expand and create efficiencies.”

MacroSolve president and CEO Clint Parr added, “ReForm XT is an incredibly flexible mobile tool that is the right solution for high-growth companies like Orthopedic Resources. From inventory and ordering to a more diverse set of mobility applications, ReForm XT has been selected once again as the solution of choice by smart companies.”

ReForm XT is a powerful resource that can operate within any industry. Creating a mobile application to automate business processes helps save time, decrease errors, increase productivity and delivery of up to the minute information to save businesses money and increase revenues. For more on ReForm XT please visit http://www.goanyware.com/products/reformxt/.

For information regarding Orthopedic Resources please visit www.orthopedicresources.com.

About MacroSolve
MacroSolve, Inc. is a pioneer in delivering mobile apps and solutions to businesses and government. Founded in 1997, the company has an extensive network including the top name brands in wireless hardware and software as well as carriers. MacroSolve’s mission is to become the leader in delivering mobile business apps, a market projected to grow by double digits to $11.6 B by 2012. The company operates through its subsidiaries including Anyware Mobile Solutions (http://www.goanyware.com/). For more information, visit http://www.macrosolve.com/ or call 800-401-8740.

Safe Harbor Statement
 This press release contains projections of future results and other forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Important factors that may cause actual results and outcomes to differ materially from those contained in the projections and forward-looking statements included in this press release are described in our publicly filed reports. Factors that could cause these differences include, but are not limited to, the acceptance of our products, lack of revenue growth, failure to realize profitability, inability to raise capital and market conditions that negatively affect the market price of our common stock. The Company disclaims any responsibility to update any forward-looking statements.

Click here to see all recent news from this company

NORTH KINGSTOWN, RI–(Marketwire – August 18, 2010) –   Amazing Charts, Inc., a leading developer of Electronic Health Record (EHR/EMR) systems, today announced the visit of Rhode Island Congressman Jim Langevin (RI-02). During the visit, Congressman Langevin viewed a presentation by Amazing Charts founder and CEO Jonathan Bertman, MD about the recent legislative impact on healthcare technology and EHRs, as well as the company’s history of job creation and future roadmap.

“We are honored to have Jim Langevin as our guest at Amazing Charts today,” said Dr. Bertman. “As physicians, we feel like we are being forced by the government and insurers to adopt EHR technology and it is important that we were able to brief the congressman on impacts that the Federal stimulus package will have on healthcare technology decisions.”

With the Federal Government providing as much as $27 billion over the next 10 years for physicians to computerize patients’ medical records (HITECH/ARRA), the bulk of the presentation focused on the effects of the Federal stimulus on the EHR market, the overpricing of EHRs and the need for transparency at all levels, including health insurance companies and Regional Extension Centers, which exert a powerful influence on physician purchasing decisions.

Among other topics discussed was Amazing Charts being honored as the fastest growing private company in Rhode Island by Inc. Magazine’s Inc. 5000 list and their contribution to local job growth.

About Congressman Jim Langevin (RI-02)
Congressman Jim Langevin was elected to the US House of Representatives in 2000 and has served in the Second Congressional District ever since. Langevin is a member of both the Democratic Regional Whip for New England and the House Majority Whip for Jim Clyburn’s Senior Whip Team. Among his other interests, Langevin has been recognized as a national and party leader on health care issues. 

About AmazingCharts.com
AmazingCharts.com provides Electronic Health Records (EHR/EMR) and services to small healthcare practices. Amazing Charts V5 is a CCHIT Certified® 2008 Ambulatory EHR, additionally certified for Child Health. Based on number one ratings for usability, fair pricing, and overall user satisfaction, the Amazing Charts EHR is used by more than 3600 practices and is growing by over 70 new practices each month. Founded in 2001 by a practicing family physician, AmazingCharts.com, Inc. is headquartered at 1130 Ten Rod Rd, F-207, North Kingstown, RI 02852, 1-866-382-5932.

Amazing Charts is a trademark of AmazingCharts.com, Inc. All products or service names mentioned herein are trademarks of their respective owners.

Click here to see all recent news from this company

TEMPE, AZ–(Marketwire – August 18, 2010) –  Current figures estimate that spending on health care in the U.S. is about 16% of its GDP. In 2007, an estimated $2.26 trillion was spent on health care in the United States, or $7,439 per capita. Health care costs are rising faster than wages or inflation, and the health share of GDP is expected to continue its upward trend, reaching 19.5% of GDP by 2017.

With health care reform recently approved, the debate over costs is fierce. Some say costs will be controlled or reduced; others claim that costs will spiral out of control. Regardless, Medicare, in its present form, is not sustainable, according to the Congressional Budget Office.

On the sidelines in the debate over care and costs is a rising trend toward alternative health care, known as naturopathy. Tempe, Arizona based naturopathic physicians Danite Haller, N.D. and Eric Udell, N.D. at Arizona Homeopathic Associates are enjoying a thriving practice in spite of national economic woes. “With many people out of work and not having company health insurance, they are finding that naturopathic medicine is an effective and affordable way to go,” claims Udell.

Naturopathic medicine is based on the belief that the human body has an innate healing ability. Naturopathic doctors teach their patients to use diet, exercise, lifestyle changes and innovative natural therapies to enhance their bodies’ ability to ward off and combat disease.

Dr. Haller describes the difference between conventional medicine and naturopathy, “In naturopathy we don’t use medication to alleviate or mask symptoms. We strive to identity the causes of the symptoms and provide non-invasive treatments and no pharmaceutical medicines.” Haller and Udell have chosen one aspect of naturopathy — homeopathy. First used in 1796 by a German physician, homeopathy uses specially prepared remedies based on the law of “similar.” This means substances that cause certain symptoms can be use in extremely diluted form to encourage the body in the healing process. These remedies are all natural and have no side effects.

Homeopathic remedies are extremely cost effective, costing less than traditional medications. Naturopathic care, which requires greater doctor care and interaction than conventional medicine is less costly, too.

For more information on this alternative form of medical care, see www.azhomeopathic.com.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – August 17, 2010) –  Maimonides Medical Center Urologist Dr. Ridwan Shabsigh, director of the Division of Urology, answers viewers’ health questions on a recent episode of his online medical advice and health talk show, “The Dr. Ridwan Show.” Along with his elite panel of experts, Drs. Harry Fisch, Michael Perelman and Richard Sadovsky, Dr. Ridwan offered sound medical information to very common men’s health questions. Based on the premise, “Ask the Doctor — Health information you can use,” the show helps deliver men’s health information in a user-friendly format.

Dr. Ridwan and his experts fielded a question on frequent fatigue. They explained that fatigue is a common problem in men and women. They cautioned that fatigue could be a symptom of anemia, chronic inflammation, infection or other chronic medical problem. It could also have something to do with sexual hormones, signifying a decline in testosterone that results in less energy and vitality. It could also represent depression or lack of quality sleep. They cautioned viewers to not disregard fatigue and visit their doctor.

The experts also discussed topics such as heart disease, high blood pressure and lower back pain. The doctors said that chest pain could be a serious symptom and it should always be investigated further. When Dr. Ridwan examines his patients, he goes beyond the symptoms, asking them what is important in life to them. Ridwan feels that if patients are honest about their symptoms and lifestyle habits, he can get to the root of the problem.

A viewer wrote in with a question about her husband’s snoring. The doctors explained that the snoring could be symptomatic of something serious, such as sleep apnea, which is frequently associated with obesity. Dr. Ridwan advised the viewer to have her husband see a doctor and also evaluate testosterone levels or any possible sexual problems.

Dr. Ridwan and his experts also discussed a viewer’s question on men’s exercise. The viewer asked how often he should exercise and how he could get motivated to exercise. The panelists advised the viewer to start with walking and gradually become more active with fun activities that he enjoys. They suggested exercise should be done a minimum of 150 minutes a week, as there are health and negative consequences that can occur from not exercising enough.

Click here to see all recent news from this company

MUNDELEIN, IL–(Marketwire – August 17, 2010) –  Speaking yesterday in New York City before more than 150 U.S. hospital executives, Dr. Mark Chassin, president of The Joint Commission, expressed an optimistic view for the U.S. healthcare system long term and outlined a “quality driven strategy” to rein in costs and improve efficiency. At the same time, he cautioned that if both society as a whole and individual health care systems do not “get control” of healthcare costs, the country could face the consequences of greater payment cuts and “big” benefit reductions. The Joint Commission is the country’s predominant standards-setting and accrediting body in healthcare.

Chassin made these comments as the keynote speaker at the third annual “Prevention Above All” conference hosted by Medline Industries, Inc. The conference brings together hospital executives from around the country to discuss practical solutions to improving patient safety and delivering cost-effective quality care.  

Chassin identified three broad ways to improve U.S. healthcare. The first is to eliminate the overuse of health services. He cited several examples, including excess use of imaging services and prescribing antibiotics for the common cold. The second issue is reducing the waste and inefficiencies created by the growing complexity for routine health care processes. Studies have indicated, he said, that as much as 25-30 percent of nursing time is wasted (and could be recovered for patient care) if we simplify our processes for everyday care such as dressing changes and medication delivery. Finally, Chassin identified the chronic problem of our inability to eliminate preventable complications such as healthcare associated infections.

“If we can achieve these three solutions, we can save money and improve quality,” he said, “and we would be able to solve the basic conundrum of how to pay for effective care for everyone in this country without having to go to severe restrictions on benefits and payments.”

Chassin did offer one sobering warning if we fail to reduce spending. “As a last resort, due to federal deficits and out of control healthcare costs, we could face real rationing, which means the active denial of effective care,” said Chassin. “Every other developed country does a pretty good job of delivering quality healthcare and spends far less, often less than half of what we do on a per capita basis. I think we can get there.” 

In addition to Chassin, the conference also included prominent international healthcare leaders Atul Gawande, surgeon and best-selling author; John Nance, contributor to ABC News and best-selling author; Robert F. Kennedy, Jr.; Andrew Cuomo, New York State Attorney General; Trent Haywood, senior vice president of clinical performance and chief medical officer for VHA, Inc.; Didier Pittet, a member of the advisory board of the WHO World Alliance for Patient Safety; Linda Groah executive director and CEO of the Association of Perioperative Operating Room Nurses (AORN).

About Medline Industries, Inc. 

Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to extended care facilities, hospitals, surgery centers, home care dealers and agencies and other markets. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services. 

NEW YORK, NY–(Marketwire – August 17, 2010) –  Healthcare is a niche market with growth potential for Smartphones, according to healthcare market research publisher Kalorama Information. The firm cites high rates of physician use of Smartphones and PDAs and available applications among many factors making healthcare ideal for Smartphone sales. In 2009, PDAs and Smartphones for healthcare applications were worth about $2.6 billion combined — according to Kalorama’s recently released report, “Handhelds in Healthcare: The World Market for PDAs, Tablet PCs, Handheld Monitors & Scanners.”

Kalorama notes that the industry is no stranger to portability. Healthcare professionals have been key consumers of beeper and pager devices, and many portable patient record and reference book products have been aimed at physicians. While healthcare is just a fraction of total Smartphone and PDA sales, just about five percent of the total market, Kalorama predicts that healthcare is one of the growth areas — particularly for Smartphones, because of their ability to combine communication with alerts, references and records.

“Healthcare is a mobile profession and lends itself to these devices,” according to Bruce Carlson, Publisher of Kalorama Information. “They provide a wide range of conveniences and workflow efficiencies which can’t be achieved with traditional notepads and pocket drug references.”

The firm notes that several wireless companies have tailored their product offerings to the needs of the healthcare industry and expects this to continue. Last year Socket Mobile, Inc. released the SoMo 650Rx hospital-grade PDA featuring an antimicrobial material that provides improved protection against the spread of bacteria and microbes. Motorola’s MTC100 offers a host of features designed to enhance productivity and effectiveness — equipped with multi-mode wireless connectivity, secured wide-area data bearer, and wireless LAN connection. In 2006, Beiks LLC released a talking English-Spanish translator for the BlackBerry platform (RIM) for emergency workers. This application is directed toward paramedics who often operate in environments with both English and Spanish speaking patients. The system was first released with 800 essential words and phrases, covering common questions, commands, people, places, conditions, drugs, medications, anatomy terms, and more.

Additionally, iPhone usage in healthcare is evidenced by the number of applications available for physicians. Various media outlets have reported over 1,700 medical apps existed as of last year, and that number has most likely grown since then.

“Handhelds in Healthcare: The World Market for PDAs, Tablet PCs, Handheld Monitors & Scanners” contains more information on Tablet PCs, Smartphones, PDAs, as well as handheld monitors and scanners, with forecasts for each of these segments. Profiles of competitors and trends in handheld technology in healthcare are also included. The report can be found at:
http://www.kaloramainformation.com/redirect.asp?progid=79476&productid=2703662.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

WEST HARTFORD, CT–(Marketwire – August 17, 2010) –  ORLive, the vision of improving health, presents new video focusing on surgical options for type 2 diabetes, from NewYork-Presbyterian. In addition to these videos, ORLive invites you to take part in the latest installment of the Virtual Brain Tumor Board, and go back to school this month as your watch and learn from this month’s featured channel of medical education content.

NEW ON ORLIVE

NEW VIDEO – Surgical and Medical Treatments for Type 2 Diabetes
Premieres Tuesday, August 17, 2010 at Noon

Type 2 diabetes can lead to potentially deadly complications for many patients, but the team at NewYork-Presbyterian remains on the forefront of research and treatment innovations. Join Dr. Francesco Rubino, Chief, Gastrointestinal Metabolic Surgery at the Weill Cornell Medical Center, Dr. Judith Korner, from Columbia University Medical Center, and Dr. Louis Aronne, from the Weill Cornell Medical Center as they review the advancements that are being made and see what happens when gastric bypass surgery results in a possible remission of diabetes.

Viewers of this video are invited to interact with the team via the ORLive website, where you can also request a reminder to alert you when this video is available.

NEW CHANNEL – Sorin Group
With over 40 years of experience, Sorin Group is responsible for many of the innovations that have made heart valve replacement and repair among the safest and most effective procedures in the world today. ORLive invites you to watch and learn as Sorin presents video of many of these devices on the Sorin ORLive Channel. 

ORLIVE REFERRALS – Week of August 16, 2010
Each week ORLive highlights on-demand videos for our membership and visitors. 

Medical Education Referral: daVinci Prostatectomy Patient Education from Methodist University Hospital.

CME Referral: Critical Advances in the Evolving Science and Medicine of STEMI Management and High-Risk ACS from CMEducation Resources

Viewer’s Referral: Brain Mapping and Systems Biology from the International Brain Mapping and Interoperative Planning Society (IBMISPS)

HIGHLIGHTS

PREVIEW – Continuum® Acetabular System and Zimmer® M/L Taper with Kinectiv® Technology
Premieres Thursday, September 23, 2010 at 7PM EDT

On Thursday, September 23rd at 7 PM EDT Zimmer Medical Education will broadcast an ORLive Total Hip Arthroplasty featuring the Continuum Acetabular System and the Kinectiv Modular Neck Technology. The surgery will be performed by Dr. Mark Hartzband, Hartzband Center for Hip and Knee Replacement, L.L.C., Paramus, NJ and will be moderated by Dr. Paul Duwelius, St. Vincent Hospital, Portland, OR. The broadcast will last one hour and will show the entire surgical procedure. Following the live broadcast the surgery will be archived for future playback.

This opportunity allows for firsthand insight of the safe and effective implantation and surgical procedure involved with the Continuum® Acetabular System and the Zimmer® M/L Taper with Kinectiv® Technology.

This surgery video is available exclusively to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

NOW ON-DEMAND – DePuy^® Rotating Platform Revision Knee Replacement
Now Available On-Demand

Dr. Russ Nevins will performs a revision total knee replacement using the Sigma^® TC3 RP and M.B.T. Revision Tray system from DePuy Orthopaedics, Inc. Moderated by Dr. William Barrett (Renton, WA), this video takes place from Spring Valley Hospital Medical Center in Las Vegas, NV. 

During the video, originally presented live, Dr. Nevins performs the revision total knee replacement surgery featuring the Sigma TC3 RP, a rotating platform knee implant design. This system helps diffuse loosening forces from the increased mechanical constraint typical in revision implant systems and offers surgeons enhanced fixation options through the use of metaphyseal sleeves on the femoral and tibial side. 

Viewers can still interact with the surgical team by submitting questions via the ORLive website. To learn more about this broadcast go to ORLive.com.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>

CONCORD, CA–(Marketwire – August 17, 2010) –  Paradigm Management Services, the nation’s leading provider of catastrophic medical management services, today announced the appointment of Albert E. Holt, IV, MD, MBA, to the role of Chief Medical Officer (CMO). Dr. Holt will join the senior management team and replace Paradigm’s previous CMO and widely respected founder, Nathan Cope, MD. Dr. Cope will remain an important resource for the company as Senior Medical Officer and Board Member.

As a medical executive, clinical physician and professor, Dr. Holt is well qualified to guide the company through a new phase of success. During his seven year term at Alere, Dr. Holt served as Senior Vice President for Care and Disease Management and was responsible for managing a high-performing team of medical directors and providing medical leadership for new product initiatives. During his time, Dr. Holt restructured the industry’s largest oncology case management program to incorporate new expertise and a blended model of onsite and telephonic case management.

“When forming a transition plan with Dr. Cope,” said Paradigm President Kevin Fleming, “it was critical to both of us that his replacement shares a history of directly treating critically injured patients. With Dr. Holt, we not only gain a clinical physician, but also a talented executive skilled in shaping the types of comprehensive medical management programs for which Paradigm is known.”

Dr. Holt is a board certified physician in internal medicine and critical care. He has faculty appointments to Harvard Medical School, Georgetown Medical School and the George Washington University School of Medicine and Health Sciences. He earned his medical degree from the University of Connecticut School of Medicine, and completed his residency in internal medicine at Vanderbilt University Medical Center and critical care fellowship at the National Institutes of Medicine. He further earned his MBA in Medical Management from Johns Hopkins University in 2007. He has actively practiced critical care medicine in the Washington, D.C., area since 2005.

“I look forward to joining the management team at Paradigm during this key point in time for the company,” said Dr. Holt. “With our market expanding beyond workers’ compensation and into general liability, the development of new service offerings will be important and an exciting opportunity for me personally. I support the vision and mission of Paradigm as they lead the way in applying medical expertise to catastrophic and complex cases, while setting benchmarks for clinical and utilization outcomes.”

About Paradigm Management Services, LLC

Paradigm Management Services provides acute and ongoing catastrophic and complex case management services for traumatic brain injuries, spinal cord injuries, amputations, burns, wounds and chronic pain. As the nation’s leading provider of complex and catastrophic medical management in the workers’ compensation industry, Paradigm achieves 5x better medical outcomes and lowers total costs by 36%. Paradigm accomplishes this by bringing together nationally recognized doctors and specialists, the best network of care facilities in the country, and nearly 20 years of clinical data to guide decisions. Case In Point Magazine recently presented Paradigm with the organization’s highest honor, a 2010 Case In Point Platinum Award for the nation’s best Workers’ Compensation Case Management Program. For more information, visit www.paradigmcorp.com.

Click here to see all recent news from this company

BRANFORD, CT–(Marketwire – August 17, 2010) – Westbrook Technologies, developer of Fortis™ and FortisBlue™ enterprise document management (EDM) software, today announced that Marshall County Hospital has implemented Fortis to cut costs with speedier accounts payable and billing processes, easier collaboration between departments, and less paper storage space.

“When I started looking at which document management system would be the best fit for us, the main goal was to save space and promote better overall organization in our new facility, which opened in March of 2009,” said Patrick Waters, director of Information Technology for Marshall County Hospital. “Previously, we had filing cabinets everywhere full of paper requiring time consuming search for patient documents.

“We started first using Fortis in our accounts payable and billing departments,” Waters continued. “Staff now scan documents to easily track and retrieve invoices and purchase orders. We also use it to archive and reconcile bank statements, and for year-end reporting.” The hospital’s business office also stores Explanation of Benefits (EOB) forms. They can now retrieve and view everything they need quickly when patients have questions saving time and providing superior customer service.

KeeFORCE, a systems integrator based in Paducah, KY, implemented the software. “KeeFORCE has been great,” said Waters. “They were able to ask the right questions to make sure the initial set up was done correctly. With other systems we looked at, you got a generic set of document types and databases, and you were stuck with them. Fortis was easy to customize to meet the hospital’s specific needs.”

Waters estimates that it took less than two months from their first meeting with KeeFORCE to employee training on the system.

Marshall County Hospital also uses Fortis in the admissions department to scan in driver’s licenses, insurance cards and doctor’s orders. Fortis is integrated with CPSI, the hospital’s Health Information System, which accesses patient data from Fortis, eliminating duplicate data entry. The hospital plans to roll out Fortis to their lab, radiology and respiratory departments to give them access to doctors’ orders online. The hospital will also start scanning in employee records and contracts as well as documents related to physician credentialing.

Fortis has helped with HIPAA compliance since the system defines who can access each document type and exactly what is stored in the system. “We have been very selective about who has access to confidential information,” Waters noted. The Fortis Audit Trail automatically records these activities adding a further layer of accountability.

“Community hospitals are on the front line when it comes to healthcare delivery,” said Einar Haukeland, president and CEO of Westbrook. “With Fortis, hospitals and other healthcare organizations can expedite administrative functions and reduce storage space. These cost savings and business process improvements can directly correlate with better patient care.”

About Marshall County Hospital
Marshall County Hospital is located in Benton, Kentucky. A staff of 25 physicians offers professional medical care and approximately 250 employees staff the Marshall County Hospital and Ambulance Service. The mission of Marshall County Hospital is to provide primary and certain specialty services with high quality care, concern, dedication and value in a cost-effective manner. Since 1964, the hospital has been dedicated to the improvement of facility, services and programs that meet the needs of our community while maintaining a standard of excellence in a friendly atmosphere.

About Westbrook Technologies
Westbrook Technologies provides document management software to businesses of all sizes, from departmental to enterprise-wide implementations, and across every vertical market. The Company is the developer of Fortis document management software, in use at thousands of customer sites worldwide, to capture, index, store and retrieve critical information from anywhere — instantly and securely. Its new FortisBlue product line is a Web-based, Rich Internet Application product easily accessible from most Internet browsers. For more information, call (203) 483-6666 or visit www.westbrooktech.com.

About KeeFORCE
KeeFORCE, a Westbrook Technologies Partner, is a service-oriented technology company dedicated to identifying and providing technology solutions that promote efficiency in the workplace while satisfying the unique needs of each client they serve. Established in 1998, KeeFORCE has built a reputation built upon a foundation of customer satisfaction as a result of its commitment to providing high quality technical service with enthusiasm and integrity. Learn more at www.keeforce.com.

LEXINGTON, MA–(Marketwire – August 17, 2010) – Imprivata^®, Inc., the company that simplifies and secures access to patient information, today announced the results of its third annual online national survey that examines IT trends in healthcare. The 2010 Healthcare IT Survey polled hospitals across North America for input on securing patient health information, the move to electronic medical records (EMR) and the impact of clinician workflows on patient outcomes.

“More than one year after its passage, hospitals continue to be deeply concerned about their ability to meet deadlines imposed on them by the HITECH Act,” says Barry P. Chaiken, MD, CMO at Imprivata. “Organizations fear security breaches and unauthorized access to patient records, while trying to manage clinical transformation through the deployment of EMR systems to achieve improved care delivery and cost savings.”

Threat of Data Breaches and Negative Public Exposure Breed Real Fear
80 percent of respondents state that securing patient information from unauthorized access and data breaches is a top priority. In addition, 76 percent claim breach of confidential information or unauthorized access to clinical applications as their greatest security concerns. Yet, 38 percent still report they cannot track inappropriate access in accordance with the HITECH Act. Coupled with the fact that 76 percent of respondents are focused on investing in EMRs, this reinforces the need to protect patient health information. 

Hospitals desperately want to avoid making data breach headlines or being slapped with fines. Clearly healthcare organizations are worried about unauthorized access to patient health information, data breaches and meeting HITECH Act disclosure mandates. Therefore it is imperative that they safeguard patient information while maintaining a simple, yet robust system that helps them simplify compliance reporting and minimize negative public exposure. 

Keeping Physicians Happy is all about Workflow and Applications
Securing patient information continues to be critical for healthcare organizations. Patient information lives in applications that physicians and staff rely on each day, and they demand access to this information without disrupting their daily routines or forcing them to alter how they practice medicine. Despite advances in strong authentication, passwords remain the most popular form of application access security and more than 90 percent of respondents state that passwords and time to access patient data negatively impact physician satisfaction, which has a direct impact on patient care. 

Hospitals need to bridge the gap between clinician productivity and IT security. Understanding clinician workflow and dependence on applications to provide quality patient care, it is imperative that hospitals secure user access without re-engineering established clinician workflows.

The results of the 2010 Healthcare IT Survey demonstrate that hospitals across North America struggle to balance the need to secure patient information with the reality that it is not feasible to change well-established workflows. The repercussions of data breaches and exposure of patient information are clearly understood, and it is now squarely on healthcare organizations to both provide easy clinician access to patient information and enforce patient privacy –
 without compromising on either.

The survey polled 600 healthcare IT decision-makers across the U.S. and Canada. Full results and an executive summary of the 2010 Healthcare IT Survey can be downloaded or requested by email via [email protected].

About Imprivata
With more than 500 hospitals and one million healthcare users, Imprivata is the leading independent vendor focused on simplifying and securing access to electronic patient health information. By making patient data easily accessible, enforcing patient privacy and deploying transparent security, Imprivata’s Global Healthcare Division helps customers to improve clinician workflow while achieving the security standards they demand.

Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security needs of more than 1,000 customers around the world. For more information, please visit www.imprivata.com.

Imprivata is a registered trademark of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

RSS Feed to Imprivata News: http://feeds.feedburner.com/ImprivataNews
Follow Imprivata on Twitter: https://twitter.com/Imprivata

id=”nav_links”>

LOS ANGELES, CA–(Marketwire – August 17, 2010) –  Lerner Medical Devices, Inc. (LMD) announces its continued support of professional dermatology meetings to introduce Levia®, a new class of ultraviolet (UVB) medical device. Levia provides Personal Targeted Phototherapy®, a safe and effective non-drug option for the self-treatment of scalp and small area psoriasis in the privacy and convenience of a patient’s home. In response to many inquiries, LMD is implementing a comprehensive program to inform dermatologists and dermatology nurses who are requesting additional information about Levia.

“We have received considerable interest in Levia, and we are pleased to be introducing it to hundreds of additional dermatology professionals over the next few months,” said John R. Lyon, Chief Executive Officer of LMD. “We are convinced that Levia will improve treatment effectiveness and convenience for psoriasis patients.”

Levia was demonstrated at both American Academy of Dermatology conventions this year, most recently at the Summer Meeting in Chicago, IL, August 4^th-8^th. Participation in other dermatology meetings included introduction of Levia at the Pacific Dermatologic Association’s 62^nd Annual Meeting in Pasadena, CA, August 11th-14^th and the Controversies and Conversations in Laser and Cosmetic Surgery Symposium in Carlsbad, CA, August 13^th-15^th.

Also, from September 24^th-26^th, Levia will be demonstrated to more than 200 dermatologists during the CalDerm Annual meeting in Santa Barbara, CA. The final 2010 meeting for Levia will be the Dermatology Nursing Institute (DNI) Annual Congress, October 6^th-8^th, in Las Vegas, NV.

All of the meetings are designed to educate attendees and introduce professionals to current and evolving research, as well as the newest advancements in technology to improve practice management skills and refine techniques.

For more information on Levia, Lerner Medical Devices, or any of the referenced professional meetings visit www.mylevia.com.

About Lerner Medical Devices, Inc.

Lerner Medical Devices (www.lernermedical.com) is focused on the use of ultraviolet B (UVB) phototherapy for self-treatment of psoriasis and other photo-responsive skin conditions. Levia^® is the first of their Personal Targeted Phototherapy^® products.

Levia^® provides Personal Targeted Phototherapy^® for the self-treatment of psoriasis in the privacy and convenience of a patient’s home. Levia incorporates easy to use software for physician control of dosimetry and includes two proprietary beam delivery attachments, the LiteBrush and LiteSpot, which ensure precise and safe delivery of therapeutic UVB light.

To learn more about Levia® and Lerner Medical, please visit www.mylevia.com.
Find Levia on Facebook: http://www.facebook.com/mylevia
Follow Levia on Twitter: http://www.twitter.com/mylevia
Follow Ask Nurse Linda on Tumblr: http://asknurselinda.tumblr.com

Click here to see all recent news from this company

WAKEFIELD, RI–(Marketwire – August 17, 2010) –  ChartWise Medical Systems, Inc. (www.chartwisemed.com) is pleased to announce that it has established an OEM relationship with MicroStrategy (www.microstrategy.com), a leading worldwide provider of business intelligence software. ChartWise: CDI is a new software program that assists hospitals to improve clinical documentation to help maximize DRG-related reimbursements, reduce Medicare audit risk, and provide oversight and compliance. Through the MicroStrategy Business Intelligence platform, the ChartWise: CDI system will include a dashboard that will provide detailed reporting and comprehensive analysis of documentation data available in ChartWise: CDI. The dashboard will provide administrative users of ChartWise: CDI with access to key facility-wide financial and medical metrics and the data to measure improvement program effectiveness. In addition, customers will be free to analyze and present their data in a wide variety of formats. The new business intelligence functionality of ChartWise: CDI is an additional option that will be available by the end of 2010.

“By working with MicroStrategy we are bringing a new dimension and additional value to ChartWise: CDI. This new set of features will give hospital administrators the tools to go beyond our standard reporting package and drill down further into their data, which is very important given the challenges that many are facing,” said Dr. Jonathan Elion, creator of ChartWise: CDI. “Providing hospitals with the clinical documentation intelligence needed to maximize reimbursements and the tools by which to measure results uniquely positions ChartWise: CDI to help hospitals become more efficient.”

About ChartWise
ChartWise Medical Systems, Inc. based in Wakefield, RI, is a medical software firm and the developers of ChartWise: CDI and ChartWise: CDI Personal Edition, a hosted solution for clinical documentation improvement. ChartWise: CDI’s clinical intelligence expertise assists physicians and clinical documentation specialists with increased efficiencies and completeness of documentation, queries and work flow. Developed by renowned physician, Jon Elion, M.D., ChartWise: CDI is the only documentation software that translates clinical language used by physicians into accurate diagnostic language required for Medicare documentation. For more information, visit www.chartwisemed.com.

YARDLY, PA–(Marketwire – August 17, 2010) –  Xyntek, Inc., a global leader in IT, automation and compliance solutions, today announces XyNexus™ Healthcare Integration Service, the consolidation of its healthcare IT services that address healthcare information technology (HIT) integration and development aspects, as well as electronic healthcare records (EHR) infrastructures. XyNexus™ is expected to be especially attractive to customers in pursuit of ARRA funding for implementation of Meaningful Use requirements.

The XyNexus™ Healthcare Integration Service team has the expertise to deliver on complex integration requirements involved in HIT planning, assessment, selection, implementation, roll-out, migration, and support of multiple healthcare information solutions as well as healthcare information exchanges (HIE).

“Our XyNexus™ Healthcare Integration Service methodology combines an ideal balance of tools, talents, techniques, and cost management. Healthcare IT organizations that are interested in creating and maintaining a dynamic HIT infrastructure have a reliable partner in Xyntek,” said Mac Hashemian, P.E., President and Chief Executive Officer of Xyntek Inc.

XyNexus™ Healthcare Integration Service manages such applications as:

• Connectivity — Internal and External Systems
• Data Migration — including analysis, definition, and optimization of requirements and system architecture
• Healthcare Enterprise Application Integration
• Healthcare Information Exchange
• Laboratory Information Management
• Regulatory Compliance Management
• System-to-System Messaging / Brokering
• Trading Partner Management
• Transaction Processing
• System Migration (ICD9 to ICD10)
• User Authentication using Biometrics

Hospitals and medical providers rely on Xyntek’s advanced techniques and experienced staff to provide reliable and optimized integration services for the entire HIT lifecycle to ensure that they have well-designed, efficiently optimized technical environments. XyNexus™ Healthcare Integration Service implements technical excellence to ensure HIT implementations for hospitals and provider organizations are successful. Xyntek prides itself on improving healthcare processes by integrating solutions into existing and optimized workflows.

About Xyntek

Xyntek, a global leader in IT, Automation and Compliance solutions, has had its focus on healthcare information technology since its inception in 1986. Its veteran team of consultants have extensive healthcare information technology experience and provide advanced integration solutions for organizations focused on gaining visibility and access to data, working within aggressive timelines, internalizing healthcare processes and operations using external resources, and companies looking to integrate and consolidate data from multiple service providers and sources. Xyntek’s business is based on providing high-end technical services and solutions that allow customers to maximize the benefits of IT and Automation technologies, while adhering to compliance mandates. For more information, visit www.xyntekinc.com.

Click here to see all recent news from this company

FRIENDSWOOD, TX–(Marketwire – August 17, 2010) – TrinityCare Senior Living, Inc. (OTCBB: TCSR) (the “Company”), which develops, manages and owns faith-based senior living facilities, today announced its operating results for the second quarter of 2010. 

For the six months ended June 30, 2010, the Company reported gross revenues of $3,461,586, which represented an increase of 10% when compared with gross revenues of $3,141,804 in the six months of 2009. Gross profit totaled $2,200,112, compared with $1,847,555 for the six months ended June 30, 2009. The Company’s gross profit margin reflected 62% of gross revenue in the most recent six month period, versus 65% in same period of the prior-year. The Company reported a net loss of ($402,191), or ($0.03) per share for the six months ending June 30, 2010, versus a net loss of ($721,167), or ($0.47) per share, in the prior-year period.

“This represents our fifth consecutive quarter of revenue growth, when compared with prior-year periods,” stated Donald W. Sapaugh, Chairman and Chief Executive Officer of TrinityCare Senior Living, Inc. “Our occupancy rates remain stable, and with revenues increasing, we expect the Company’s operating results to improve as we focus on controlling expenses. Existing operations are critical to our long-term success, and we have devoted significant resources to ensuring that our financial metrics improve in coming quarters. During the most recent quarter we have expanded our services to include management of facilities which are not owned by TrinityCare and we expect continued growth in that segment of our business in the near future.”

About TrinityCare Senior Living, Inc.

TrinityCare is a rapidly growing company that develops, owns and manages quality senior living facilities that focus on enriching the faith of residents while providing state-of-the-art independent living, assisted living, memory care and adult day care services in a single location. The Company partners with local churches and developers for each facility and offers a wide range of both community and personal services to residents. 

Headquartered in Friendswood, Texas, the Company currently operates three successful facilities in Texas and Tennessee. Near-term expansion plans are focused upon markets in the Southeastern U.S. For additional information, please visit www.trinitycare.com.

(Financial Highlights Follow)

LOS ANGELES, CA–(Marketwire – August 16, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (jointly, “the Company” and “MMR”) (www.mmrglobal.com) today filed its quarterly statement for the six months ended June 30, 2010.

Revenues for the first six months from sales of the Company’s consumer and professional products, MyMedicalRecords, MyEsafeDepositBox and MMRPro, were up by 58.6% over 2009. Total sales for these products, including Deferred Revenue (the portion of the Company’s sales that is to be recognized monthly over the term of agreements with our customers), have increased by 94%. Total Revenues for the three months ended June 30, 2010, including the Company’s core products and licensing fees, were up by 21% as compared to 2009. Total sales for the same period, including Deferred Revenue, were up 60.7% as compared to 2009.

According to Ingrid Safranek, the Company’s Chief Financial Officer, “We reduced total liabilities by $2.4 million or 28.5%. In addition, we reduced Accounts Payable by $451 thousand or 15%. Although we disclosed an Accounts Payable balance of $2.5 million, $1.6 million of that balance is attributable to the reverse merger with Favrille, Inc. and only $272 thousand represents MMR trade payables necessary to operations. Accordingly, we maintain good relationships with our vendors.”

Safranek continued, “In the last quarter, we were able to issue equity in lieu of cash to reduce liabilities by $1 million. We plan on using our equity to further reduce liabilities and strengthen our balance sheet based on our vendors’ belief in the value of the Company. Our ability to issue equity for services has afforded us the opportunity to support sales of MMRPro and other advertising and marketing programs as well as continuing to exploit patent opportunities with our biotech assets. Only $1.2 million of our loss was cash-related. The remaining amount represents non-cash expenses driven by $5.6 million from the application of accounting principles to value derivative liabilities and equity as well as an additional $1.0 million from stock options, warrants and common stock issued for services. These warrants and stock options have enabled us to obtain services that a Company our size would not otherwise have been able to afford.”

According to Robert H. Lorsch, Chairman and CEO of MMRGlobal, “We are well on our way toward executing on our business plan to achieve a global footprint from which we will sell our proprietary line of Personal Health Record (www.mmrvideos.com) and MyEsafeDepositBox (www.myesafevideos.com) products and MMRPro professional medical record products and services (www.mmrprovideos.com). However, growing a technology company in health care costs money. Accordingly, we are incurring increasing costs necessary to our growth. For example, we are now deploying development teams both in the U.S. and China to support the UNIS-TongHe transaction.” 

“We are also expanding technical and development resources at home with increased staff in support of MMRPro,” said Lorsch. “This includes adding resources necessary to provide services that will meet meaningful use criteria and enable customers who use our products to qualify for government stimulus around the world. In addition, we are relocating our most experienced development resources to the U.S. from Nihilent headquarters in India to work with our management team and our customers directly.”

“Also, I plan on being in India in October for the launch of a Nihilent and MMRGlobal joint sales effort to small-sized health care professionals, hospitals and the government in India. At the same time, we are also increasing the size of our processing, hosting and IT infrastructure, adding more feature-rich facilities designed to reduce cost and increase scalability which should ultimately improve margins,” added Lorsch.

The Company has also begun the process of spending significantly more money on advertising, marketing and sales promotion using television (www.mmrontv.com) the web and through affiliate partnerships. An example is the “$25.00 Check-Up” refund program which launched on the Company’s MyMedicalRecords.com website today. 

MMR is also in the process of upgrading MMRPro (www.mmrprovideos.com), the Company’s professional document imaging and management system for health care professionals. For instance, recently added features enable forms to be customized to an existing office practice resulting in the ability to access customized forms from MMRPro on demand. As such, doctors are able to use the forms they use today and still continue to move toward meaningful use.

Additionally, the Company is working with several major hospital groups to help market MMRPro systems to doctors associated with these specific hospital groups. This is part of a program designed to help monetize MMRPro patient upgrades. Also, MMR is starting to call on physician offices in the United States through the Kodak nationwide reseller channel.

Patient upgrades enable health care professionals to take advantage of the MMRPro “Stimulus Program” (http://mmrvideos.com/stimulus). This program creates a revenue stream for physicians from patient upgrades. The Company believes that its Stimulus Program can generate more than twice the $44,000 in revenue for physicians than the government’s HITECH Act stimulus program in much less time.

The Company continues to actively explore opportunities with its pre-merger Favrille biotech assets. In association with GRSworldwide, MMRGlobal is working to bring its anti-CD20 monoclonal antibodies to market. These antibodies are potentially useful in treating B-Cell malignancies, including Non-Hodgkin’s Lymphoma (NHL) and additional B-Cell mediated conditions such as rheumatoid arthritis. MMR’s anti-CD20 antibody asset is potentially a candidate for a next generation of Rituximab, marketed under the trade name Rituxan® in the United States by Biogen Idec and Genentech (wholly owned member of the Roche Group) and under the name MabThera® by Roche in the rest of the world except Japan, where it is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd. Rituxan/MabThera is one of the world’s most successful monoclonal antibodies with reported total sales in 2009 in excess of US$5.6 billion.

MMRGlobal also continues to pursue various national phase filings from the Patent Cooperation Treaty patent application directed to the anti-CD20 monoclonal antibodies, including in the United States, Australia, Brazil, Canada, China, Europe, India, Japan, South Korea and Mexico. The Company has further been addressing opportunities pertaining to intellectual property rights involving B and T cell vaccine technology relative to the FavID vaccine in various stages in the United States and foreign countries through its reverse merger with Favrille. MMRGlobal is also in the process of filing certain patents regarding numerous aspects of the FavID vaccine, a portion of which has been recently granted. 

The Company continues its activities in support of the launch of the Chartis-branded MyEsafeDepositBox product, which plans to provide MMR’s secure online virtual safe and Personal Health Record products and services to Chartis policyholders worldwide, while it further works with Chartis on opportunities to offer its products domestically as well.

Additionally, MMRGlobal is in active negotiations with one of the world’s largest financial institutions regarding the development of paperless loan processing and delivery solutions whereby loan documents can be delivered electronically through the Company’s MyEsafeDepositBox product, with resultant completed documents being filed in a permanent online MyEsafeDepositBox account.

“We are pursuing several Merger and Acquisition opportunities that could accelerate growth, expand the Company’s product line and enable us to offer more services consistent with criteria for meaningful use, specifically PHR and EMR related,” Lorsch added. “We have always intended to grow MMR into a much larger organization. However, it takes money and patience to grow a company. For example, Amazon went public in 1997, and had a net loss of $31 million, followed by a net loss of $125 million, and almost $720 million in 1998 and 1999, respectively. In their last annual report for the year ended 2009, they had net income of $902 million.”

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward Looking Statement
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Any comparisons made with other companies are for illustrative purposes only and do not imply any similar levels of growth, revenue, or income. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company’s products are not adopted or viewed favorably by the health care community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; variations in our quarterly operating results; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the health care industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company’s marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. 

Click here to see all recent news from this company

LONDON, ENGLAND–(Marketwire – Aug. 16, 2010) – IDBS, the leading worldwide provider of data management and analytics solutions to R&D and healthcare organisations, announces that, as the result of continuing expansion, and growth in demand for its products and services, revenues for the six months ended 30 June 2010 rose by 20% on the same period of 2009 to $20.3 million, with profit before tax also growing strongly.

These results follow the excellent progress made in 2009, for which IDBS reported 12% revenue growth to $36.4 million, with the company sustaining healthy underlying profitability and margins and completing the cash acquisition of InforSense in June 2009.

Excluding the impact of InforSense, underlying revenue growth was well into double digits with underlying profit before tax significantly up on the first half of last year. This reflects growing and recurring revenues from existing customers as well as projects completed for new customers.

Revenue for the first half of 2010 benefited from a strong product performance in the company’s core pharmaceuticals market where organisations are seeking to improve the effectiveness of their business processes and the use of high-value data. Key to growth for the period was the implementation of significant projects, involving the E-WorkBook Suite, at a number of major companies for drug formulation and preclinical development, and at a contract manufacturer of biologics for process development improvement.

Software sales for the period grew by 44% on the first half of 2009 with maintenance revenues increasing by 13% and professional services by 25%.

Since the acquisition of InforSense, IDBS has established a leading position in the high-growth market of biomarker and personalised medicine research, recently winning a number of new contracts which will benefit the second half of 2010 and beyond. These include a significant engagement with Barts Hospital and the London NHS Trust to improve the understanding of cardiovascular disease in the UK.

“R&D companies and healthcare organisations recognise the strategic value of IDBS in process improvement projects, enhancing regulatory compliance and research collaboration,” commented Neil Kipling, founder and CEO of IDBS. “Our reputation and market leadership are based on our data management expertise and solutions combined with an unrivalled understanding of scientists, the R&D process and the needs of our customers. We are continuing to invest in the business and to strengthen our relationships with existing and new customers. As a result, we are confident that IDBS is on track to achieve its best ever financial performance in 2010 and to continue to make strong progress thereafter.”

During the period, IDBS was included in the 2010 ProfitTrack100 list of private companies, recognising the company’s long-term record of sustained, profitable growth.

About IDBS

IDBS is a unique, global supplier of innovative data management and first-in-class analytics solutions which increase efficiency, reduce costs and improve the productivity of Healthcare R&D organisations. Multinational pharmaceutical companies, major public-private healthcare partnerships, global leaders in academic study and high tech companies employ IDBS as a strategic supplier of scientific informatics and business process improvement solutions. IDBS is clearly differentiated from other providers by its unique combination of deep domain knowledge across the entire R&D sector: from the examination of the human genome at the scientist’s bench, through the clinic, to translational medicine initiatives and pay-for-performance healthcare monitoring. IDBS solutions support the protection of Intellectual Property and the requirements for data quality and security demanded under Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and HL7 (Health Level) standards. IDBS improves organisational efficiency, releases the value stored in organisations’ R&D data assets and enables effective collaboration through secure scientific data sharing.

IDBS is a ProfitTrack 100 private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, as well as the EU, Australia and China. Further information can be found at www.idbs.com.

DEURLE, BELGIUM–(Marketwire – August 16, 2010) –  Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the first quarter ended on June 30, 2010 (in US Dollars).

Net sales for three months ended June 30, 2010 increased 62% to $3.4 million compared to $2.1 million for the same year ago quarter. The increase in sales was due to the inclusion of our Asian retail operations as well as the sale of First Fit.

Profit for the three months ended June 30, 2010 prior to outside shareholders participation totaled approximately $568 thousand compared with losses of $488 thousand for the same year ago quarter. Profits attributed to Remedent common stockholders for three months ended June 30, 2010 was $312 thousand compared to losses of $549 thousand for the same year ago quarter.

Cash and cash equivalents totaled $1.2 million at June 30, 2010 as opposed to $613 thousand as reported at March 31, 2010.

Management Commentary

“The shifting of our business model from wholesale (B2B) model via a distributor to a direct retail model is beginning to bear fruit as previously mentioned during prior conference calls. During the current quarter we included our retail Asian operations of approximately $600 thousand in gross revenues as we are continuing to open new Spa locations in both Europe and Asia during the next quarter and in the remainder of our financial year. Sales in all our Spa locations continue to exceed our expectations as sales continue to climb,” said Guy De Vreese the CEO of Remedent.

Conference Call Information

Remedent will host a conference call on Wednesday, August 18, 2010 at 11:00 a.m. Eastern Standard time (8:00 a.m. Pacific time) to discuss these results and its strategic plans for the future. A question and answer session will follow management’s presentation. To participate in the call, dial the appropriate number 5-10 minutes prior to the start time.

Date: Wednesday, August 18, 2010
Time 11:00 a.m. Eastern time (8:00 a.m. Pacific time).
Dial in number: 888-765-5547
Passcode: 4258061

The replay of the call will be available through September 15, 2010. The dial in number for the replay is 888-203-1112 and the replay pass code is 4258061

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and cosmetic dentistry products. The company serves professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com.

Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release that are “forward-looking statements” are based on current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expects,” “expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,” “plan,” “projects,” “project,” to be uncertain and forward-looking. Actual results could differ materially because of factors such as Remedent’s ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent’s business, please refer to the risk factors described in Remedent’s filings with the Securities and Exchange Commission, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q.

INDIANAPOLIS, IN–(Marketwire – August 16, 2010) – iSALUS Healthcare, one of the country’s top web-based electronic medical records (EMR-EHR) software and medical practice management software companies that serves small and medium sized physician practices, today announced a newly formed strategic partnership with the Indianapolis Medical Society (IMS). Through this exclusive endorsement, iSALUS will offer discounted electronic medical records (EMR-EHR) and practice management software subscriptions to more than 2,000 IMS members.

As part of the strategic partnership, iSALUS will offer Indianapolis Medical Society members a pre-negotiated discount for subscriptions to its entire suite of services. These include medical office and practice management software (billing, collections, scheduling, rounds, dictation, charge capture, automated workflow) and electronic medical and health records software (electronic charting, lab interfaces, e-prescribing, automated letters, integrated faxing and document management technology). In addition to software, iSALUS also will provide IMS members with localized training, technical support and customer service.

“The Indianapolis Medical Society is pleased to strengthen our relationship with iSALUS. The company has demonstrated proven leadership in EMR-EHR and practice management software. One of our goals as an organization is to continue to offer practice enhancement opportunities to our physician members; this partnership allows us to do just that,” said John C. Ellis, MD. “Additionally, iSALUS allows our members to purchase individual modules for their medical practices, making the transition to EMR-EHR technology as simple or as diverse as a member requires. We have hands-on experience as to how well the iSALUS EMR-EHR software works since we have used it since 2004 for the IMS Foundation’s Project Health, our outreach initiative for the uninsured residents of Marion County.”

The Indianapolis (Marion County) Medical Society was founded in 1848 and has more than 2,100 members representing approximately 67 percent of the physicians in the greater Indianapolis area. It is a professional membership organization for licensed Doctors of Medicine and Doctors of Osteopathy. The IMS is a component of the Indiana State Medical Association and the American Medical Association. For more information, please visit: www.imsonline.org.

“iSALUS has been an associate member of the Indianapolis Medical Society since 2003,” commented Michael Hall, president and founder of iSALUS Healthcare. “We are proud to contribute to the advancement of the medical industry and to IMS’ members’ success. Our EMR-EHR and practice management software is ideal for IMS’ membership base which is comprised of primarily small to mid-sized physician practices. Through this partnership we will be able to help members achieve Meaningful Use of electronic health and medical records (EMR-EHR), as well as increase the efficiency of their practices and improve patient care.”

About iSALUS Healthcare
Founded in 2000 and headquartered in Indianapolis, iSALUS Healthcare offers web-based, mobile-optimized EMR-EHR and practice management software solutions exclusively for small to medium sized physician practices, healthcare offices and medical clinics. Its proven suite of easy-to-learn and easy-to-use applications is accessible from any Internet connection and provided at an affordable monthly fee. iSALUS includes unlimited technical support and customer service with all of its software subscriptions. Throughout its history, the company has served thousands of doctors and practice managers across the country. For more information, please visit www.isalushealthcare.com or call 888.280.6678.

WEST HARTFORD, CT–(Marketwire – August 13, 2010) –  ORLive, the vision of improving health, presents a live broadcast of a revision knee replacement presented by DePuy. This week ORLive welcomed Sorin Group, and you can view their library of prosthetic heart valves and repair device videos on the Sorin ORLive Channel. In addition to these videos, ORLive invites you to take part in the latest installment of the Virtual Brain Tumor Board, and go back to school this month as your watch and learn from this month’s featured channel of medical education content.

NEW ON ORLIVE

LIVE SURGERY VIDEO – DePuy^® Rotating Platform Revision Knee Replacement
Live August 12, 2010, 7:00 PM

Dr. Russ Nevins will perform a revision total knee replacement using the Sigma^® TC3 RP and M.B.T. Revision Tray system from DePuy Orthopaedics, Inc. The broadcast will be moderated by Dr. William Barrett (Renton, WA). This broadcast will take place from Spring Valley Hospital Medical Center in Las Vegas, NV. 

At 4PM Pacific (7PM EDT), Dr. Nevins will perform the revision total knee replacement surgery featuring the Sigma TC3 RP, a rotating platform knee implant design. This system helps diffuse loosening forces from the increased mechanical constraint typical in revision implant systems and offers surgeons enhanced fixation options through the use of metaphyseal sleeves on the femoral and tibial side. 

Viewers are invited to interact with the surgical team by submitting questions via the ORLive website. To learn more about this broadcast and to sign up for an e-mail reminder go to ORLive.com.

NEW CHANNEL – Sorin Group
With over 40 years of experience, Sorin Group is responsible for many of the innovations that have made heart valve replacement and repair among the safest and most effective procedures in the world today. ORLive invites you to watch and learn as Sorin presents video of many of these devices on the Sorin ORLive Channel. 

ORLIVE REFERRALS — Week of August 9, 2010
Each week ORLive highlights on-demand videos for our membership and visitors. 

Medical Education Referral: Innovations in Transcatheter Valve Therapies from NewYork-Presbyterian.

CME Referral: New Frontiers in the Science and Medicine of Venous Thromboembolism from CMEducation Resources

Viewer’s Referral: New Options for Advanced Heart Disease from Montefiore Medical Center

HIGHLIGHTS

PREVIEW – Surgical and Medical Treatments for Type 2 Diabetes
Premieres Tuesday, August 17, 2010 at Noon

Type 2 diabetes can lead to potentially deadly complications for many patients, but the team at NewYork-Presbyterian remains on the forefront of research and treatment innovations. Learn what advancements are being made and see what happens when gastric bypass surgery results in a possible remission of diabetes. Don’t miss “Surgical and Medical Treatments for Type 2 Diabetes,” August 17th at Noon.

Viewers of this video are invited to interact with the team via the ORLive website, where you can also request a reminder to alert you when this video is available.

NOW ON-DEMAND — EVOLUTION™ Medial-Pivot Knee System
Now Available On-Demand

Designed to replicate the function of a normal knee, the EVOLUTION™ Medial-Pivot Knee is one of the newest total knee systems on the market. This surgery was performed by Dr. David DeBoer, and he answered questions from the audience during the broadcast. Learn the latest on the knee system that was built utilizing state-of-the-art design and manufacturing technologies…don’t miss “EVOLUTION™ Medial-Pivot Knee System.”

This surgery video is available to members of the ORLive community, and members can still interact and ask questions via the ORLive website. Learn more about this broadcast at ORLive.com, and view this exciting procedure by activating your free membership to ORLive today.

NOW ON-DEMAND — Prenatal Pediatrics
Now Available On-Demand

Managing a high risk pregnancy can be difficult. NewYork-Presbyterian Morgan Stanley Children’s Hospital provides the maternal, fetal and pediatric expertise to care for high-risk pregnancies. NewYork-Presbyterian Morgan Stanley Children’s Hospital was one of only eight hospitals in the country ranked in each medical specialty measured by U.S. News & World Report, with distinct leadership in neonatology and pediatric cardiac surgery.

Join Dr. Mary D’Alton, Chair, Department of OB/GYN, Columbia University College of Physicians and Surgeons, and a team that includes Dr. Richard Polin, Director, Neonatology, as they review the capabilities and treatments available at the Center for Pediatrics. 

Viewers of this video are invited to interact with the team via the ORLive website, and to join the community and receive regular updates from the NewYork-Presbyterian Morgan Stanley Children’s Hospital Center for Neonatal Pediatrics.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>

RIVERSIDE, CA–(Marketwire – August 13, 2010) – ONRAD, Inc., a leading radiology services provider, announces its support for The Association for Medical Imaging Management (AHRA) by exhibiting at the 38th Annual Conference in National Harbor, MD. “We are pleased to be a part of the exhibition in 2010,” said Ryan Pahler, Director of Sales and Marketing at ONRAD. “We are always adding to our service offering and I look forward to sharing our newest solutions with the attendees at the conference.”

Visit ONRAD at Booth #424 to learn about the company’s complete radiology solution, which can include teleradiology services, technology consulting, subspecialty teleradiology interpretations, and professional radiology staffing. As a partner, ONRAD provides more than just teleradiology interpretations. The ONRAD executive team develops strategies to help each customer be more competitive in their local community.

Visitors at ONRAD’s AHRA booth can also register to win a Dell Inspiron Mini 10. At only three pounds, this Netbook is easy to take anywhere in the hospital. Those that can’t make it to the show can enter to win by subscribing to the ONRAD blog. The blog contains healthcare and radiology news and encourages participation from industry thought leaders. Subscribe to the blog and become part of a network of other radiology professionals focused on sharing ideas and improving their businesses. Subscribe to the ONRAD blog.

For more on this topic, visit: http://www.onradinc.com/?page_id=1867.

About ONRAD:

ONRAD is a full service physician-owned radiology provider offering customized radiology services including teleradiology solutions, professional staffing, and technology services. As a partner, ONRAD helps its customers increase profitability and improve patient care. Through a unique hybrid model that combines on-site staffing with supplemental teleradiology coverage, ONRAD can provide a significant cost savings.

About AHRA:

The Association for Medical Imaging Management (AHRA) is the professional organization representing management at all levels of hospital imaging departments, freestanding imaging centers, and group practice. Founded in 1973, AHRA’s 4000 members reach across the country and around the world. AHRA offers a complete slate of professional development programs including a comprehensive selection of educational conferences and seminars, networking opportunities, award winning publications, and the Certified Radiology Administrator (CRA) credential.

Click here to see all recent news from this company

LOS ANGELES, CA–(Marketwire – August 13, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) today announced it will release financial results for the second quarter ended June 30, 2010 after the close of market on Monday, August 16, 2010. The Company expects to exceed expectations for the first six months of 2010.

“We are continuing to execute on our business plan, expanding globally, moving offices, and doubling the size of our IT infrastructure in the United States while deploying development resources in China,” said Robert H. Lorsch, Chairman and CEO of MMRGlobal. “We’re excited about the interest in MyEsafeDepositBox from financial institutions. We are actively involved in pursuing M&A opportunities in our core business of personal and electronic health records and patent opportunities with our biotech assets. Additionally, next week we will launch the first-ever online promotion program to consumers designed to encourage them to better health by activating a MyMedicalRecords Personal Health Record account (www.mmrvideos.com). MMRGlobal is an entrepreneurial company, and like a NASA where many commercial products and services are a byproduct of its core space missions, we believe our technologies can generate many ways to provide life-saving tools that can be offered to a variety of business and industries. Although we began with Personal Health Records, we continue to develop new products and relationships, such as with Kodak and Chartis International.”

The Company believes that the restructuring of the healthcare system in the United States will continue to present ongoing opportunities for uses of its products and services to consumers, healthcare professionals and corporations.

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheater.com.

Forward-Looking Statements
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue.” MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal, Inc.’s business prospects, results of operations or financial condition, government regulation, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – August 13, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced the pricing of an underwritten public offering of 26,750,000 million shares of its common stock at a price to the public of $7.75 per share. Sun has granted the underwriters a 30-day option to purchase up to 4,012,500 additional shares of its common stock to cover over-allotments, if any. Sun expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $195.3 million from the offering, or $224.8 million if the underwriters exercise their over-allotment option in full. The offering is expected to close on Aug. 18, 2010, subject to customary closing conditions.

Sun intends to use the net proceeds from this offering to repay a portion of the outstanding term loans under its existing credit facility.

Jefferies & Company, Inc., Credit Suisse Securities (USA) LLC and J.P. Morgan Securities Inc. are the joint book-running managers for this offering.

This press release does not constitute an offer to sell or a solicitation of any offer to buy the shares of Sun’s common stock described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The offering may be made only by means of the prospectus supplement and the related prospectus relating to the offering, copies of which may be obtained by written request to Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12^th Floor, New York, NY 10022, by telephone at (877) 547-6340, or by e-mail at [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010 or by telephone at (800) 221-1037.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25 states, of which 22,427 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary.

Forward-Looking Statements

Statements made in this release that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,” “may” and similar expressions. Factors that could cause actual results to differ are identified in the public filings made by the Company with the Securities and Exchange Commission and include our ability to successfully complete the offering on terms and conditions satisfactory to us, as well as other risks and uncertainties, including those detailed from time to time in our Securities and Exchange Commission filings. More information on factors that could affect our business and financial results are included in our public filings made with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on Sun’s web site, www.sunh.com. The forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control. We caution investors that any forward-looking statements made by Sun are not guarantees of future performance. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

NEW YORK, NY–(Marketwire – August 12, 2010) –  Vaccines continue to be the success story for pharmaceutical companies, with the world market for preventative vaccines totaling $22.1 billion in 2009, up from $19 billion in 2008, according to healthcare market research publisher Kalorama Information. Kalorama’s new report, “Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry,” notes that the worldwide vaccine market is predicted to increase at a compound annual rate of 9.7% during the next five years, as new product introductions continue and the use of current products expands further. 

“We’ve forecasted a high growth rate for vaccines over the past few years and market events have matched our predictions,” said Bruce Carlson, publisher of Kalorama Information. “The vaccine business is not without its risks, but for some companies, vaccines were the only bright spot in their portfolio in 2009. It’s not a surprise therefore that development is heavy in this sector, and that will contribute to growth over the next five years.”

Vaccines are commonly segmented into two target markets, adult and pediatric. According to Kalorama Information, the pediatric vaccine market is larger, accounting for more than half of the total market. Pediatric vaccines are also growing at a faster rate than adult vaccines and this is expected to continue over the next five years. Pneumococcal and “combination” DTaP vaccines are driving growth in the pediatric sector, while influenza and hepatitis vaccine products are driving sales in the adult segment of the market. Future growth in adult vaccines will be driven by increased acceptance and new products. 

The worldwide vaccine market is dominated by five major competitors: Merck & Co, GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis. These companies have made earning a greater share of the vaccine market part of their marketing and research strategies. GlaxoSmithKline is in the lead with nearly a quarter of the world market in 2009, largely due to its influenza products Fluvarix and Hiberix, according to Kalorama. 

More information is available from Kalorama Information’s report, “Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry,” including market forecasts, company profiles, and trends in the industry. The report can be found at: http://www.kaloramainformation.com/redirect.asp?progid=79452&productid=2684026.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

CINCINNATI, OH–(Marketwire – August 12, 2010) –  Technology Medical Partners (TMP), a healthcare information technology solutions and services provider, today announced that Holzer Medical Center, an Ohio-based hospital, has implemented TMP’s Clinical Quality Manager (CQM) solution to improve patient care and reporting of quality of care core measurements. The CQM platform will help Holzer focus on improving patient outcomes by automating quality data collection, analytics and reducing processing time for reports required by the Centers for Medicaid and Medicare Services (CMS). Holzer serves the communities of southeastern Ohio, western West Virginia and northeastern Kentucky.

TMP’s CQM solution provides Holzer the ability to abstract quality of care data from any system; provide reports and dashboards to anyone; and support analytics and quality improvement anywhere; functions that are not provided by most electronic health records (EHR) systems at this depth or completeness. TMP’s CQM solution is built on the Microsoft SharePoint portal platform and abstracts patient data and other information from across Holzer’s disparate departments and systems, including its EHR systems. Holzer’s staff and medical professionals will no longer take months to manually complete all of the required CMS reports. Because the data is automatically captured, populated and formatted in report forms, CQM’s automated reporting process will reduce the processing time by months.

“The system is impressive and I cannot wait to have more real-time data on my desktop regarding quality measures,” stated Jim Phillippe, CEO and President of Holzer Medical Center. “Focusing on core measures is key to improving quality scores, and I am also glad to see how this system relates to the reporting of the Meaningful Use of our EHR system.”

“The CMS quality reporting process continues to become more complex, and having a system that will streamline data collection and report completion will allow us to use the data in real time to improve our patient care and focus on quality outcomes,” said April McLain, Quality Director for Holzer Health System. “By improving reporting efficiency, our management, doctors and nurses will have convenient access to real-time quality data on their desktops via dashboards. This will allow for analysis of the core measure data months in advance of the current process. With faster, more accurate CMS reporting, we can improve processes and outcomes, and we will be eligible for additional government funds based on Pay for Performance. We plan to use this real time data to analyze and improve our readmission rates.”

From CQM’s dashboards, Holzer’s staff can aggregate and abstract patient information that can be used to track patients’ treatments, programs and outcomes. The aggregated information from across the health system will also help administrators to follow and report on Hospital Acquired Conditions (HACS), Readmission Rates by DRG, Patient Satisfaction, evidence-based medicine processes, and automate forms, documents, schedules and other staff functions. Additional applications are planned.

“For Holzer and other healthcare providers, having access to the right data at the right time (real-time quality data) is critical to ensuring that patients receive better care and outcomes in the long run,” said Jim Dixon, managing partner at TMP. “As our tag line says, ‘Quality Data Improves Outcomes.’ Our CQM system provides medical professionals with the real-time information and efficiencies they need to focus on patient outcomes while providing hospitals with a means to improve its tracking and reporting processes to improve compliance, profitability and competitiveness. We appreciate the trust Holzer has put in our solutions and look forward to helping them continue to make their patients the center of all they do.”

About Holzer Health Systems
Since 1909, the name Holzer has been synonymous with wellness in the community. Today, Holzer Health Systems offers a wide and comprehensive range of services, including the most advanced healthcare, diagnostics, and treatments available. Headquartered in Gallipolis, Ohio, Holzer serves the needs of patients in southeastern Ohio, western West Virginia and northeastern Kentucky. For more information, visit www.holzer.org.

About Technology Medical Partners
TMP’s Clinical Quality Manager vastly improves the Quality of Care, data abstraction and administrative processes related to reporting quality core measures to anyone. Founded in 2004, TMP is a Microsoft Certified ISV and is focused on Healthcare Quality Improvement with Composite Software Solutions based on SharePoint and other Microsoft products. TMP delivers value-added information technology solutions and services to the Healthcare Industry. We focus on the business improvement of healthcare providers (Hospitals, Clinics and Physician Practices). TMP brings a comprehensive array of software solutions, platform products and implementation services together with experience and leadership in Healthcare Solutions delivery. For more information, please visit www.t-m-partners.net

Click here to see all recent news from this company

PHOENIX, AZ–(Marketwire – August 12, 2010) –  The Arizona Heart Institute is pleased to announce its support of the newly integrated alliance between Vanguard Health Systems (Nashville, TN), Arizona Heart Institute, and Arizona Heart Hospital. This follows Vanguard’s recent announcements to acquire the Arizona Heart Institute (AHI) and the Arizona Heart Hospital (AHH). If approved, both AHI and AHH would join Vanguard’s Abrazo Health Care system which includes five hospitals throughout the Phoenix area, Abrazo Medical Group, and two health plans, Phoenix Health Plan and Abrazo Advantage.

“The Arizona Heart Institute physician-member investors in the Arizona Heart Hospital enthusiastically endorse this sought-after partnership,” said Edward B. Diethrich, MD, founder and medical director of Arizona Heart Institute and Arizona Heart Hospital. “With AHI and AHH as Vanguard entities, both organizations would operate under a single leadership and management, providing the opportunity to strengthen and streamline all aspects of patient care from diagnosis through treatment and rehabilitation. Also, this places the new organization in a better position to compete for insurance contracts and leverage the capital and management skills associated with a larger corporation,” according to Diethrich.

The Arizona Heart Institute out-patient physician practice is part owner in the Arizona Heart Hospital, LLC, a 59-bed in-patient facility owned by the North Carolina-based MedCath Corporation. Earlier this year, MedCath Corporation announced its plans to sell the Arizona Heart Hospital.

“For many months, we have been evaluating several potential suitors to acquire the Arizona Heart Hospital and the Arizona Heart Institute. In Vanguard, we found a natural fit,” commented Diethrich. “While Vanguard offers us the possibility of more scalable and reproducible programs, they too are committed to addressing the issues most important to Arizona Heart — preservation of our name and identity, support of our tradition of research and education, and exemplary patient care.”

Since AHI’s inception in 1971, AHI’s clinical research and medical education activities have been led and operated by the for-profit Arizona Heart Institute which is known for a long list of achievements including Phoenix’s first heart transplant, Arizona’s first coronary stent, its pioneering role in aortic aneurysm endografting, and the world’s first hybrid endovascular suite. During the campus reorganization, AHI recently transferred its research and education programs to the Arizona Heart Foundation, a non-profit, 501(c)(3) organization. “While these programs will continue under the direction of the AHI physicians who over many years have worked hard to make them successful, the Foundation will be in a much better position on the operational and administrative fronts to apply for research grants, fundraise, partner with academic centers, and continue to improve programs like International Congress,” said Diethrich.

“We believe that this new alliance with Vanguard in collaboration with the non-profit Arizona Heart Foundation accomplishes the potential for escalated excellence in cardiovascular research, a tradition that has long been the cornerstone of the Arizona Heart mission,” according to Venkatesh G. Ramaiah, MD, Director of Peripheral Vascular Research at the Arizona Heart Institute. “The partnership enables us to expand our clinical research efforts to supply leading edge technology and research for both diagnosis and treatment of cardiovascular diseases. These efforts in the past have yielded enormous capabilities in caring for patients with serious blood vessel and heart ailments. We anticipate under this new collaboration that even more exciting and productive accomplishments will occur in the near future,” continued Ramaiah.

“Since the inception of the Arizona Heart Institute over 40 years ago, medical education has been a high priority,” said Julio A. Rodriguez-Lopez, MD, Director of Peripheral Vascular Surgery and the Fellowship Program at the Arizona Heart Institute. “The training of physicians, nurses, and technical staff has distinguished us as an education leader. The new affiliation with Vanguard and our expanded relationship with the Arizona Heart Foundation will assure continued advancement in our educational endeavors.”

About Arizona Heart Institute

Arizona Heart Institute is among the world’s leading providers of cardiovascular care. This visionary organization was founded in 1971, quickly evolving into the country’s first freestanding outpatient clinic solely dedicated to the prevention, diagnosis and treatment of heart and blood vessel disease. Since then, Arizona Heart Institute has grown to expand treatment and research options with the opening of Arizona Heart Hospital in 1998 and the dedication of Arizona Heart Institute Translational Research Center in 2007. Through these unique facilities, Arizona Heart Institute offers the most contemporary and comprehensive approach to cardiovascular medicine and an unmatched level of specialty care. For more information, visit www.azheart.com.

LOUISVILLE, KY–(Marketwire – August 12, 2010) –  Bringing home the gold is always an incredible accomplishment. This year the University of Louisville along with its architectural team of SmithGroup and Arrasmith, Judd, Rapp, Chovan Inc. are basking in the glory of gold for the design and construction of the new Clinical and Translational Research Building.

In the quest to continue to excel in the biomedical sciences nationwide, the University’s Health Sciences Center (HSC) embarked on the design of the Clinical and Translational Research building (CTR) in 2004. The facility was to be a continuation of the goals of creating state-of-the-art research facilities in order to attract and retain the best researchers from among the nation, consolidate existing programs, and provide for the opportunity to augment on the success of programs already established within the HSC.

Completed in August 2009, the $109-million, 288,000 gsf facility consists of a combination of wet laboratories, laboratory support spaces, shared equipment/support areas, auditorium, and research faculty offices. The building’s bright, colorful and vibrant interior lab and office environments were designed to facilitate discovery and groundbreaking research. Of primary importance is the open laboratory concept utilized in the facility, which allowed lab planning experts to design laboratories as larger spaces housing various investigators rather than dedicated smaller modules assigned to a single investigator, thus increasing collaboration.

Achieving LEED Gold Certification was clearly one of the greatest accomplishments in this particular project. These days it is more common for buildings to pursue certification, but it is extremely rare that certification isn’t actually pursued until the project is well into construction. The design team, contractor and owner met to discuss the possibility of pursuing LEED late in the game and determined that certification would be achievable since the team incorporated various sustainable design measures from the beginning. These measures included providing daylighting to 75% of occupied spaces, selecting eco-friendly and recyclable materials, and commissioning all equipment including fumehoods.

The Clinical and Translational Research Building project is the fourth in a series of research buildings SmithGroup has designed with partner AJRC. SmithGroup and AJRC have a long history on the University of Louisville campus. Their partnership dates back over 30 years and includes research buildings, classrooms and clinical expansion at the University of Louisville campus. In addition, the team designed the university’s research tower, library center, dental school, clinical core hospital building, an ambulatory care building, and the Donald Baxter and Delia Baxter Research Buildings.

SmithGroup ranks as the 7^th largest architecture and engineering firm in the U.S. (Building Design & Construction “Giants” survey, July 2009) and employs 800. The firm is composed of client industry-focused practices serving the higher education, healthcare, workplace and science & technology markets.

With 346 LEED accredited professionals and 45 LEED certified projects, SmithGroup is a national leader in sustainable, environmentally intelligent design. Among its most noteworthy, recently completed projects are the dual LEED Platinum Christman Building, a corporate headquarters in Lansing, Mich.; the LEED Platinum Smart Home at Duke University, Durham, North Carolina; and the National Renewable Energy Lab’s Science & Technology Facility, Golden, Colo., the first LEED Platinum federal project.

Established in 1853, SmithGroup is the longest continually operating architecture and engineering firm in the U.S. 

NORMAN, OK–(Marketwire – August 12, 2010) – Access Plans, Inc. (OTCBB: APNC), a leading membership benefits marketing company, today announced that the Company will host an investor conference call to discuss its operating results for the third quarter and first nine months of FY2010 at 11:30 a.m. Eastern Time (EDT) on Monday, August 16, 2010. The Company will release its operating results earlier the same day.

Shareholders and other interested parties may participate in the conference call by dialing 877-317-6789 (international/local participants dial 412-317-6789) and asking to be connected to the “Access Plans, Inc. Conference Call” a few minutes before 11:30 a.m. EDT on August 16, 2010. The conference call will also be available via “live” webcast under the Investor Relations section of the Company’s website at www.accessplans.com, or by visiting http://www.videonewswire.com/event.asp?id=71766  to access the webcast directly.

A replay of the conference call will be available one hour after the call through Tuesday, August 24, 2010 at 9:00 a.m. EDT by dialing 877-344-7529 (U.S.) or 412-317-0088 (international) and entering the conference ID Number 443633.

An archived version of the webcast will also be available under the Investor Relations section of the Company’s website at www.accessplans.com.

About Access Plans, Inc.

Access Plans, Inc. (OTCBB: APNC) is a leading membership benefits marketing company with two distribution channels. The Wholesale/Retail Plans distribution channel specializes in turnkey, private-label membership benefit plans that provide discount products and services, protection benefits and retail services to more than 1 million customers in the United States and Canada. America’s Health Care Plans (AHCP), the Company’s Insurance Marketing distribution channel, is one of the nation’s largest independent agent networks and provides major medical, life and supplemental insurance products to individuals. For more information, please visit: www.accessplans.com.

LAGUNA HILLS, CA–(Marketwire – August 11, 2010) –  Today, Iconosys, Inc., a leader in mobile communications technology, announces a first in terms of integrating the world’s primary new means of communication, text messaging, with the needs of professionals in Real Estate, Medical Offices, Dental Offices, and for appointment setters of all types.

Originally a research and development project designed to explore possibilities and further enhance the wildly popular texting while driving apps already offered by Iconosys’ SMS Replier™ (www.smsreplier.com) and DriveReply™ (www.drivereply.net) products, Mighty SMS™ has now evolved into a text message scheduling system that allows professionals to setup reminders for their clients and patients and enables them to send their clients and customers friendly courtesy notices/reminders prior to their scheduled meetings and thank you notes afterward.

Mighty SMS™ comes in a personal version, where all features are managed on the phone itself, or in a professional version with more functionality; the app can be administered through an internet interface, and scheduling can be done in real time (right in front of the patient, or while on the phone with a sales lead) and as your appointments are being scheduled. The web interface/management comes at a nominal monthly fee. Also, while the company is excited about its plans for integration of this app into Google Calendar and Outlook in the near future as a plug-in for ease of management by office staff and appointment setters, at present Mighty SMS™ is fully functional and ready to meet the heavy demands of the busy professional or house-spouse.

As of now, a personal user can use it to pre-program text message salutations to their friends, loved ones, and professional contacts. Thank You’s, Happy Birthday’s, and Happy Anniversary’s are not accidentally forgotten when you input your Mighty SMS™ onto your phone and utilize this to organize your calendar and your contacts.

In the Professional version, customized replies can be generated that remind clients and patients of upcoming appointments, with information about contacting you back if there are any changes. 

“Already a favorite among dentists here in Orange County, CA, the dentists are seeing a lower volume of cancellations and ‘forgetting’s,’ as patients that made appointments sometimes months earlier, and may have completely forgotten their appointment, get a friendly non-threatening personal message from their favorite service provider (dentist, doctor, optometrist, hairstylist, chiropractor, contractor, MONAVIE rep, etc.),” commented Wayne Irving, CEO of Iconosys, Inc. Mr. Irving continued, “It’s great for car salesmen or others in sales that want to pre-program a thank you message for a couple days later after the sale, to send good wishes and work for that return customer and high rating of customer satisfaction.”

Texting or text messaging has become a significant portion of our population’s first means of communication. Less formal than an email, more convenient than a phone call or voicemail, and more secure than instant messaging, text messaging has become our tool for meaningful introductions when two people wish to express or share short messages without getting into deep conversations, for reasons like lack of time, while still providing a sense of personal fulfillment and significance to the recipient for the “thought that counted” when they receive a wish for good tidings.

Text messaging is a great way to share short personal bits of data between people that share responsibilities, like parents and or partners in a company. It’s a great way to send addresses and other short bits of info that do not require a full conversation, and without the risk of leaving a voicemail that may not get listened to for days and days.

“I use text messaging for every possible communication I can. It allows me to talk to more people, get more done in less time, and keep tabs on my employees, without having to go through all the greetings and salutations and small talk all the time. I don’t do it ALL the time, but it sure helps me to build my business and be more productive wherever I am, while also allowing me to regularly and consistently stay in touch with the people I work with and to convey a ‘job-well-done’ or to give them constructive advice where appropriate,” said Jeffrey Weiss, CTO for Iconosys, Inc.

Mighty SMS™ is available to the personal User for $3.99 per month, and for the Business or Professional user at $59.99 per year. The integrated web interface tools are scheduled to be made available in September for Professional users only at a $39 per month maintenance fee. Professional users price includes 60 minutes of tech support per year for setup, changes, and migration advice. The service currently requires a Windows Mobile 6.5 or Windows Phone 7. The company plans to offer this product on the Android platform when the Android Tablet is released closer to Christmas 2010.

Mighty SMS™ is pending availability on the Windows Marketplace, but until then it can be downloaded from www.Handango.com, www.CNET.com, www.PayLoadz.com and www.MightySMS.com.

About Iconosys, Inc.

Iconosys, Inc. is developing a series of technologies designed to make mobile applications better, faster, easier, and ultimately safer to use. Iconosys’ flagship product, SMS Replier™, is a revolutionary mobile phone application designed to couple many convenience services with addressing the growing problem of communicating safely while driving a car, truck, or motorcycle.

Iconosys’ CEO Wayne Irving II, a pioneer in next-generation telecom concepts, has led the drive to take advantage of GPS and other onboard motion technologies to build lifesaving and life-enhancing products and utilities, and to create new and better tools for wireless platforms and mobile device operating systems.

Iconosys proprietary technology, developed with support from Motorola, is a complex series of algorithms and readings from the technology running on today’s Smartphones; this includes, without limitation, GPS and other motion sensoring, coordinated with Google mapping to provide an accurate and responsive background service to most, if not all, of the upcoming Iconosys technology releases. Iconosys’ DriveReply™ technology tests up to 90% more efficient in battery consumption while using ordinary GPS technology, a key differentiator for Iconosys, when competing with other producers of GPS dependent Smartphone applications. 

For more information, including demonstration videos, on Iconosys, Inc, please visit: http://www.iconosys.com or http://www.mightysms.com. 

For further information about Iconosys, Inc. and its products or for interviews with CEO Wayne Irving II, please contact Adam Mazur at 212-843-8073 or [email protected]. High-resolution images and instructional videos available upon request. Follow Mighty SMS™ on twitter: @mightysms

Click here to see all recent news from this company

SAN JOSE, CA–(Marketwire – August 11, 2010) –  Beginning on September 23^rd, the Patient Protection and Affordable Care Act will allow consumers who purchase new or revised insurance plans or policies to receive an array of preventive care services with no out-of-pocket cost. The Foundation for Health Coverage Education (FHCE), www.CoverageForAll.org, while applauding any efforts to keep overall health care costs down, cautions that this provision could instead lead to out-of-control medical costs which will escalate insurance premiums.

“While mammograms and colonoscopies clearly provide preventive services that are cost-effective and can save lives, one has to question the government’s waiving the total cost to the consumer for smoking cessation, and weight loss and alcohol treatment, which are included in these mandated services. A line must be drawn by the government as to where its funding ends and where personal responsibility begins,” said Phil Lebherz, FHCE Founder and Executive Director. 

“Behavior modification programs represent a billion dollar industry with high recidivism rates. As a result, because they will be available at no cost, enrollments in programs to combat the effects of lifestyle diseases from smoking, obesity and alcoholism will ratchet up costs with little expectation that the consumer be responsible for making healthy lifestyle choices,” said Lebherz.

The new law will require that individual policies and employer-based health plans offer certain mandated preventive health care services with no out-of-pocket costs to Americans
when they enroll in either new individual health policies or new group health plans. Going forward, the consumers with the new policies or plans will not be charged a co-payment, coinsurance or deductible for certain preventive services performed by a network provider, doctor or testing service, covered under their policy. Consumers who keep their grandfathered plans and do not change their existing individual coverage or whose employer-based group plans are not changed considerably, won’t be eligible for mandated services that have no cost out-of-pocket expenses. 

“The government cannot legislate personal responsibility,” Lebherz said. “If it’s free, it will increase costs and accomplish little because people in counseling for obesity, alcohol, and or smoking sensation tend to backslide and readmit to programs. In fact, new policies will cost more than the grandfathered policies.”

Mandates can provide a greater range of care, but they also mean increased premiums as insurers must cover out-of-pocket costs that were originally paid by consumers. The accumulation of mandates plays an important role in raising costs. According to the Council for Affordable Health Insurance (CAHI), there are over 2,000 mandated benefits. CAHI’s studies show that mandated benefits could increase the cost of basic coverage from approximately 20% to as much as 50%, depending on the number and design of the benefits, as well as the initial cost of the premium.

“It’s important for everyone to have adequate health coverage, but we have to draw the line somewhere,” said Lebherz. “Making healthy personal lifestyle choices are within the reach of all of us,” said Lebherz.

Launched in 2004, CoverageForAll.org is America’s first public health insurance search engine, helping over two million Americans discover their public and low-cost private health insurance options. Every month 70,000 people visit the website or call the free 24/7 multilingual U.S. Uninsured Help Line (800-234-1317) to take the simple 5-question Health Coverage Eligibility Quiz and speak with a live health insurance specialist who can walk them through the process, connect them with the programs and applications and provide them with a sign-up checklist needed to successfully apply. 

For information regarding health insurance and health care reform changes, please visit www.CoverageForAll.org or call the toll-free 24/7 U.S. Uninsured Help Line 800-234-1317. The Foundation for Health Coverage Education is a 501 (c) 3 national non-profit organization with a mission to provide simplified public and private health insurance eligibility information in order for more people to access coverage.

Click here to see all recent news from this company

AUSTIN, TX–(Marketwire – August 11, 2010) –  Crossroads Systems, Inc. (PINKSHEETS: CRDS), a global provider of solutions to connect, protect, secure and restore data, today announced a global reseller alliance with Dell Services.

As healthcare providers recognize the importance of healthcare IT in providing high-quality patient care, a growing number of healthcare organizations worldwide are implementing MEDITECH healthcare information system (HCIS) applications. Dell Services works closely with healthcare organizations to optimize the long-term use of the MEDITECH system and improve healthcare delivery. In fact, Dell has received top recognition in the clinical systems sector. According to Gartner, Dell is ranked #1 for IT Services in the worldwide healthcare market, based on 2009 revenue. The company was also listed in Healthcare Informatics’ Top 100 Healthcare IT Companies.

With a growing emergence of patient privacy rights and other compliance requirements, the healthcare delivery landscape is rapidly changing, putting new pressures on IT to include fully-integrated data protection, privacy and security solutions within their MEDITECH environment.

Under this new alliance, MEDITECH customers will be offered Crossroads’ products — starting with Crossroads TapeSentry and SPHiNX solutions, which have been certified by Dell Services for MEDITECH, to take advantage of key data protection features such as efficient virtual tape backup, powerful encryption, and replication technologies. These offerings include:

TapeSentry as an appliance solution providing secure tape encryption using a robust key management system.

SPHiNX as a dedicated virtual tape appliance offering optimized data protection and resiliency for Windows server environments.

“Crossroads’ solutions continue to attract organizations within highly sensitive industries such as healthcare and finance,” said Rob Sims, President and CEO of Crossroads Systems. “Through our reseller alliance with Dell Services, we can extend our reach of the Crossroads’ SPHiNX and TapeSentry solutions within clinical environments worldwide — where data privacy, protection and security are of the upmost importance.”

“Information Technology is integral to improved patient safety and quality of care. As the HIPAA Act, and more recently, the HITECH ACT attest, safeguarding electronic protected health information must be every healthcare executive’s priority. The partnership of Dell Services and Crossroads is uniquely positioned to bring cost-effective, proven data protection solutions to a large segment of the MEDITECH community,” said John Ebel, Senior Manager, MEDITECH Solutions Group, Dell Services.

About DELL
Dell Inc. (NASDAQ: DELL) listens to customers and delivers worldwide innovative technology and business solutions they trust and value. Dell Services develops and delivers a comprehensive suite of services and solutions in applications, business process, consulting, infrastructure and support to help customers succeed.

Dell is a trademark of Dell Inc.

About Crossroads Systems
Headquartered in Austin, Texas, Crossroads Systems, Inc. is a leading provider of solutions to connect, protect, secure and restore data. Crossroads (PINKSHEETS: CRDS) trades over-the-counter on Pink Sheets and posts its financial disclosure reports, press releases and other related documentation on the OTCIQ Web service of the Pink Sheets Web site. Visit www.crossroads.com.

Forward-Looking Statements
This release may include forward-looking statements. The words “believe,” “expect,” “intend,” “plan,” “project,” “will” and similar phrases as they relate to Crossroads are intended to identify such forward-looking statements. These statements reflect the current views and assumptions of Crossroads and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.

©2010 Crossroads Systems, Inc. Crossroads and Crossroads Systems are registered trademarks of Crossroads Systems, Inc. All specifications are subject to change without notice.

Click here to see all recent news from this company

BURBANK, CA–(Marketwire – August 11, 2010) –  Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Thursday August 12, 2010 at 1:00pm PST, (4:00pm EST) the company’s CEO, Mr. Dean Janes, will be hosting a conference call. To join the conference call, please call 1-888-373-5705 and enter passcode 364039 followed by the pound sign (#). You will be connected to the conference call in a listen only mode, and then lines will be opened for questions following the presentation.

The purpose of the call is to update Shareholders and other interested parties of the current developments with the company.

A limited number of lines will be available for this conference call. The lines will open up 5 minutes prior to the start of the call.

A recording of the conference call will be made available on the company’s website as soon as it is available. Imaging3 will notify shareholders and others who subscribe to the company newsletter. Anyone who would like to be added to this list is encouraged to sign-up for the e-mail based newsletter on the company’s website using the following link — http://www.imaging3.com/newsletters_signup.html.

About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information.

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Aug. 10, 2010) –

(NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA)

Medifocus Inc. (TSX VENTURE:MFS)(PINK SHEETS:MDFZF) (“Medifocus” or the “Company”) announces the completion of a private placement of 2,449,997 Units (the “Units”) at a price of $0.30 per Unit for gross proceeds of $734,999. Each unit is comprised of one Common Share and one Series A Common Share purchase warrant. Each Series A Common Share purchase warrant will entitle the holder to purchase one additional Common Share at a price of $0.50 for a period of 24 months following the closing of the offering. If, at any time prior to April 26, 2012, the daily volume weighted average trading price of the Company’s common shares on the TSX Venture Exchange exceeds $0.75 for at least 10 consecutive trading days, the Company may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given.

Securities issued in connection with the private placement and any shares issued upon the exercise of the warrants will have a hold period in Canada until December 7, 2010.

The net proceeds of this offering will be primarily used to initiate a pivotal phase III clinical trial using the Company’s Microfocus APA 1000 System for the treatment of breast cancer (including all related professional expenses) and for working capital.

Medifocus also announces that it is in the process of finalizing the previously announced debt settlement with certain third party creditors, employees and service providers. Subject to approval by the TSX Venture Exchange, Medifocus will issue an aggregate of 3,592,105 common shares at an aggregate deemed price of $0.50 per common share to settle such outstanding debt. The common shares issued will be subject to hold periods pursuant to applicable securities laws as well as the policies of the TSX Venture Exchange.

Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array (“APA”) technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. Please visit www.medifocusinc.com for more details.

COLD SPRING, NY–(Marketwire – August 10, 2010) –  Though it sounds strange enough, the “stickiness” of your medical website is critical to its ultimate success. It is the way you get visitors to your site, keep them there and get them to return over and over. “Your website needs to make a good impression in order for your potential patients to spend more than 30 seconds on it,” said Daniel Gilbert, CEO of Aurora Information Technology (Aurora IT), a medical website design and physician marketing company based in Cold Spring, New York.

“The challenges in medical website marketing are endless,” explains Gilbert. “First, you have to build your site and get traffic to it. Then you have to keep them there and not click away after a few seconds thinking there is nothing there for them. Stickiness is what makes visitors into patients.”

And how is “stickiness” accomplished? Gilbert believes a good Content Management System (CMS) is vital, such as the Bitrix Site Manager that they employ in their website designs. Aurora IT is a Certified Gold Bitrix Partner and they stand behind the offerings of the product to improve a site’s traffic. “Bitrix CMS includes a series of building blocks that perform certain functions, such as blogs, calendars, newsletters, etc.,” said Gilbert, “But the Bitrix CMS goes a step beyond with features and functions that can make your medical website sticky, interactive and functional.”

Gilbert offers these CMS offering basics and value-added extras that can optimize your website’s stickiness and make it attractive to current and future patients:

Content: Relevant and updated content is the most important factor in attracting visitors. For doctors, medical condition, treatment and practice information communicate value to your visitors.

Photo Gallery: People in search of medical information are visual creatures and appreciate quality photographs, especially before and after photos and pictures of conditions and outcomes. Be sure not to have too many graphics or photos that are heavy and slow to load because most patients are not patient.

Social Networking: In addition to Facebook or Twitter, your medical website can feature social networking via forums and message boards that allow your visitors to make contributions to the site by providing comments and participating in discussions. Building community is excellent marketing.

Newsletters: Newsletters bring return visitors and are an effective form of e-marketing. They should contain useful, relevant information as well as possible promotions. Be sure to have visitors opt-in and allow them to unsubscribe easily or you will damage your reputation.

Events Calendar: Put information seminars, patient related events, workshops and more on an event calendar. Your visitors will see the value-add and you will drive more traffic not only to your site but also to your practice.

Media Player: Video and audio give your patients a dynamic, interactive experience. You can feature promotions, provide tutorials and introduce your practice to patients. The engaging nature of video and audio encourages users to spend more time on a page and help you “upsell,” because these clips can relay more essential information in less time.

“Website stickiness gets potential patients to stay and explore everything relevant to them in your website,” concluded Gilbert. “It incites them to read, interact, sign up, give feedback, and transform them from a casual surfer into a repeat visitor and future patient.”

Click here to see all recent news from this company

WEST PALM BEACH, FL–(Marketwire – August 10, 2010) – HearUSA, Inc. (NYSE Amex: EAR), a
leader among the nation’s hearing care providers, reported financial
results for the second quarter ended June 26, 2010.

Financial Results for Second Quarter 2010

In the second quarter of 2010, net revenues increased 9% to $21.4 million
from $19.6 million in the previous quarter, but decreased 6% from $22.7
million in the second quarter of 2009. The decrease year-over-year was
principally the result of some insurance plans eliminating, changing or
limiting their hearing care benefits at the beginning of 2010. The company
implemented a number of plans and strategies during the first quarter of
2010 which helped to replace most of the lost insurance business, including
increased marketing to its existing insurance base and private pay
customers. The company also increased the marketing of its AARP Hearing
Care Program and made it available to AARP members in 45 states through all
177 HearUSA centers and a network of independent AARP Hearing Care Program
providers. These combined efforts were the primary cause of the 9% increase
in second quarter revenue over the previous quarter.

The loss from continuing operations totaled $1.9 million in the second
quarter of 2010, compared to a loss of $2.5 million in the previous
quarter, and income of $963,000 in the second quarter of 2009. The loss
from continuing operations includes AARP advertising costs of $957,000
incurred in the second quarter of 2010 compared to $253,000 in the previous
quarter and none incurred in the second quarter of 2009. Advertising,
royalties and administrative costs associated with the AARP program totaled
$1.3 million in the second quarter of 2010, $588,000 in the previous
quarter and $142,000 in the second quarter of 2009.

Net loss attributable to common stockholders was $2.2 million or $(0.05)
per basic and diluted share in the second quarter of 2010, as compared to a
net loss of $2.7 million or $(0.06) per basic and diluted share in the
previous quarter of 2010, and net income of $1.1 million, or $0.03 per
basic and $0.02 per diluted share, in the same year-ago period. Net loss
attributable to common shareholders in the second quarter of 2009 included
income from discontinued operations of $336,000 or $0.01 per basic and
diluted share.

Management Commentary

“Our focus during the second quarter of 2010 was to increase revenues to
offset the loss of the managed care business in the first quarter and to
expand the reach of the AARP program,” said Stephen Hansbrough, CEO and
chairman of HearUSA. “The 9% increase in revenues over the first quarter of
2010 and the successful launch of the AARP program to AARP members in a
total of 45 states has given us a strong base for continued success going
into the third quarter.

“We have seen appointments grow at an accelerating pace since we launched
our AARP national advertising campaign, and AARP included the HearUSA
program in its publications and web sites in the latter half of the second
quarter. We expect this momentum to continue and believe that center
revenues will grow between 9% and 15% in the second half of 2010 when
compared to the first half, and our target is to grow center revenues 15%
to 20% in 2011 when compared to 2010.

“We will focus primarily on expanding the number of independent providers
participating in the AARP network during the rest of 2010 and expect to
have more than 800 participating providers by the end of the year,”
continued Mr. Hansbrough. “Both HearUSA and AARP will also continue to
increase awareness and member communications during the remainder of the
year. We believe that it will take time to fully develop the provider
network and educate the AARP membership base. Our targets for 2011 are to
expand the AARP network to more than 2,000 participating providers and
generate AARP network sales of over 30,000 units.”

Conference Call

HearUSA will hold a conference call at 4:30 p.m. Eastern time, August 10,
2010, to discuss its second quarter 2010 financial results. The company’s
senior management will host the presentation, which will be followed by a
question and answer period.

To participate in the call, dial the appropriate number 5-10 minutes prior
to the start time, request the HearUSA conference call and provide the
conference ID: 7HEARUSA.

Date: Tuesday, August 10, 2010
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Domestic callers: 1-800-862-9098
International callers: 1-785-424-1051
Conference ID#: 7HEARUSA

A Web simulcast and replay will be available via the investor relations
section of the company’s website at www.hearusa.com.

If you have any difficulty connecting with the conference call or webcast,
please contact the Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available later that evening and
will be accessible until August 17, 2010:

Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay Pin Number: 11721

About HearUSA

HearUSA is the recognized leader in hearing care for the nation’s top
managed care organizations through its 177 company-owned centers and
network of more than 2,000 hearing care providers. HearUSA is the nation’s
only hearing care provider accredited by URAC, an independent, nonprofit
health care accrediting organization dedicated to promoting health care
quality through accreditation, certification and commendation. HearUSA is
also the administrator of the AARP Hearing Care Program, designed to help
millions of Americans aged 50+ who have untreated hearing loss. For more
information about HearUSA visit www.hearusa.com, or go to
www.hearingshop.com for a wide selection of hearing related products
available for purchase online.

Forward Looking Statements

This press release contains forward-looking statements within the meaning
of the Securities Litigation Reform Act of 1995, including those statements
that HearUSA plans to expand its AARP program to include more than 800
participating independent hearing care providers during the course of 2010
and over 2,000 participating providers in 2011; that the company expects
second quarter 2010 momentum to continue; that the company believes that
center revenues will grow between 9% and 15% in the second half of 2010
when compared to the first half of 2010; that the company’s target is to
grow revenues 15% to 20% in 2011 when compared to 2010; and that the
company plans to generate AARP network sales of over 30,000 units. These
statements involve certain risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking statements.
Potential risks and uncertainties include such factors as the company’s
continuing ability to replace lost and decreased revenue from insurance
contracts with increased self-pay revenue, replacement insurance agreements
and other revenue; the company’s ability to attract and retain a sufficient
number of independent providers in all 50 states to participate in the AARP
program; the company’s ability to successfully integrate the AARP program
into its company-owned centers; the ability of the Company to capitalize on
the advertising efforts for the AARP program; the company’s ability to
control costs; the company’s ability to generate sufficient cash flows to
fund its various advertising campaigns; the ability of the company to
maintain unit sales of Siemens hearing aids; market demand for the
company’s goods and services; changes in the pricing environment; general
economic conditions in those geographic regions where the company’s centers
are located; consumer confidence in the general economy; the impact of
competitive products; and other risks and uncertainties described in the
company’s filings with the Securities and Exchange Commission, including
the company’s Form 10-K for the fiscal year ended December 26, 2009.

                               HearUSA, Inc.
                  Consolidated Statements of Operations
            Three Months Ended June 26, 2010 and June 27, 2009
                                (unaudited)


                                                 June 26,       June 27,
                                                   2010           2009
                                               ------------   ------------
                                                 (Dollars in thousands,
                                                except per share amounts)

Net revenues
Hearing aids and other products                $     19,796   $     20,653
Services                                              1,613          2,014
                                               ------------   ------------
Total net revenues                                   21,409         22,667
                                               ------------   ------------

Operating costs and expenses
Hearing aids and other products                       5,290          5,072
Services                                                412            388
                                               ------------   ------------
Total cost of products sold and services
 excluding depreciation and amortization              5,702          5,460

Center operating expenses                            12,209         10,908
General and administrative expenses                   3,769          3,661
Depreciation and amortization                           564            588
                                               ------------   ------------
Total operating costs and expenses                   22,244         20,617
                                               ------------   ------------
Income (loss) from operations                          (835)         2,050
Non-operating income (expenses)
Gain (loss) on foreign exchange                          (5)           375
Interest income                                           5              -
Interest expense                                       (841)        (1,252)
                                               ------------   ------------
Income (loss) from continuing operations
 before income tax expense                           (1,676)         1,173
Income tax expense                                     (220)          (210)
                                               ------------   ------------
Income (loss) from continuing operations             (1,896)           963
Discontinued operations attributable to
 HearUSA, Inc.
Income from discontinued operations, net of
 income tax benefit of $270 in 2009                       -            250
Gain on sale of discontinued operations                   -          1,632
Income tax expense on sale of discontinued
 operations                                               -         (1,546)
                                               ------------   ------------
Income from discontinued operations                       -            336
                                               ------------   ------------
Net income (loss)                                    (1,896)         1,299

Net income attributable to noncontrolling
 interest                                              (238)          (131)
                                               ------------   ------------
Net income (loss) attributable to HearUSA,
 Inc.                                                (2,134)         1,168
Dividends on preferred stock                            (32)           (35)
                                               ------------   ------------

Net Income (loss) attributable to HearUSA,
 Inc. common stockholders                      $     (2,166)  $      1,133
                                               ============   ============

Loss from continuing operations attributable
 to HearUSA, Inc. common stockholders per
 common share - basic                          $      (0.05)  $       0.02
                                               ============   ============
Loss from continuing operations attributable
 to HearUSA, Inc. common stockholders per
 common share - diluted                        $      (0.05)  $       0.02
                                               ============   ============

Net loss attributable to HearUSA, Inc. common
 stockholders per common share - basic         $      (0.05)  $       0.03
                                               ============   ============
Net loss attributable to HearUSA, Inc. common
 stockholders per common share - diluted       $      (0.05)  $       0.02
                                               ============   ============

Weighted average number of shares of common
 stock outstanding - basic                           44,922         44,837
                                               ============   ============

Weighted average number of shares of common
 stock outstanding - diluted                         44,922         45,340
                                               ============   ============

Amounts attributable to HearUSA, Inc. common
 stockholders:

Income (loss) from continuing operations, net
 of tax                                        $     (2,134)  $        832
Discontinued operations, net of tax                       -            336
                                               ============   ============

Net income (loss) attributable to HearUSA,
 Inc. common stockholders                      $     (2,134)  $      1,168
                                               ============   ============





                               HearUSA, Inc.
                        Consolidated Balance Sheets
                                (unaudited)


                                                 June 26,     December 26,
ASSETS                                             2010           2009
                                               ------------   ------------
                                                 (Dollars in thousands,
                                                except per share amounts)
Current assets
Cash and cash equivalents                      $      4,026   $      7,037
Short-term marketable securities                      1,306          4,106
Accounts and notes receivable, less allowance
 for doubtful accounts of $677 and $616               5,506          5,554
Inventories                                           1,409          1,844
Prepaid expenses and other                              417            464
                                               ------------   ------------
Total current assets                                 12,664         19,005
Property and equipment, net                           3,463          4,021
Goodwill                                             51,928         51,495
Intangible assets, net                               12,529         12,816
Deposits and other                                      698            731
Restricted cash and cash equivalents                  3,252          3,245
                                               ------------   ------------
Total Assets                                   $     84,534   $     91,313
                                               ============   ============

LIABILITIES AND STOCKHOLDERS'  EQUITY
Current liabilities
Accounts payable                               $      9,458   $      7,070
Accrued expenses                                      1,907          2,253
Accrued salaries and other compensation               3,224          3,520
Current maturities of long-term debt                  5,357          5,983
Income taxes payable                                      -          1,974
Dividends payable                                        35             35
                                               ------------   ------------
Total current liabilities                            19,981         20,835
                                               ------------   ------------
Long-term debt                                       33,781         36,139
Deferred income taxes                                 7,775          7,335
                                               ------------   ------------
Total long-term liabilities                          41,556         43,474
                                               ------------   ------------
Commitments and contingencies
                                               ------------   ------------

Stockholders' equity
Preferred stock (aggregate liquidation
 preference $2,330, $1 par, 7,500,000 shares
 authorized)
Series H Junior Participating
 (none outstanding)                                       -              -
Series J (233 shares outstanding)                         -              -
                                               ------------   ------------
Total preferred stock                                     -              -

Common stock: $.10 par; 75,000,000 shares
 authorized 45,451,160 and 45,381,750 shares
 issued                                               4,545          4,538
Additional paid-in capital                          138,359        137,863
Accumulated deficit                                (119,804)      (114,982)
Treasury stock, at cost: 523,662 common shares       (2,485)        (2,485)
                                               ------------   ------------
Total HearUSA, Inc. Stockholders' Equity             20,615         24,934

Noncontrolling interest                               2,382          2,070
                                               ------------   ------------
Total Stockholders' equity                           22,997         27,004
                                               ------------   ------------
Total Liabilities and Stockholders' Equity     $     84,534   $     91,313
                                               ============   ============

PHOENIX, AZ–(Marketwire – August 10, 2010) –  VALLEYLIFE, a not for profit organization committed to serving individuals with developmental disabilities, launched a sponsorship program to benefit its disabled members and invites the public to attend an open house. For more than 63 years, VALLEYLIFE has provided services to its disabled members so they might not only meet daily essential needs, but to achieve a brighter future with programs that support job training, housing, social activities, and independent living skills. 

Due to a recent termination in state funding, more than 700 disabled citizens in Arizona have been cut from their programs. At VALLEYLIFE, 17 members are directly affected and no longer receive government funding. Despite this, the staff at VALLEYLIFE has continued to provide its members the ongoing support they need. 

“Most of the members directly affected have no family. The staff at VALLEYLIFE has become their family and they, a part of ours. We will continue to provide the programs as long as we can, but without appropriate services, some of our disabled members may end up on the street or in jail,” said Cletus Thiebeau, CEO of VALLEYLIFE.

VALLEYLIFE’s sponsorship program enables local business and private citizens an opportunity to support the community they live in by providing our members with services they need to be independent. The cost to sponsor a member for one hour of service is $4, the cost of a gourmet cup of coffee. The programs range from vocational services where a member is able to earn money, to day treatment program services, where a developmentally disabled member is under the care of a qualified staff member.

VALLEYLIFE prides itself in its low administrative cost of 7 percent; 93 cents of every dollar goes directly into the programs, directly making a difference in the lives of its members. Their motto is: Changing lives. Creating Community. Today, VALLEYLIFE is humbly turning to its community for financial support so that their organization can continue to provide services to a population of people often forgotten, developmentally disabled adults.

Please show your support by calling in a monthly pledge or sending in a one-time donation. The staff at VALLEYLIFE also welcomes the public to an open house at their facility. Donors will see first-hand how even the most modest financial donation goes a long way, directly touching the lives of those who need immediate help and care.

To learn more about VALLEYLIFE, please visit www.VALLEYLIFEaz.org

Click here to see all recent news from this company

AUSTIN, TX–(Marketwire – August 10, 2010) –  As a recognized leader in the business of medical and radiation oncology, Revenue Cycle Inc. announces a new partnership with The Oncology Group. The affiliation continues a growing trend for Revenue Cycle, known for its broad-based oncology consulting work and education and training services.

As one of the premier cancer care consulting organizations in the nation, The Oncology Group will join the 3 core businesses that are Revenue Cycle: RC Billing for medical practice coding, billing, insurance submissions and AR management; Revenue Cycle consulting services which offer complete audits to measure charge capture accuracy and standards compliance; and NDevor, a healthcare facilities development company.

“We are pleased to add The Oncology Group as an affiliate and look forward to the continued growth of our companies,” says Revenue Cycle Inc. Chief Executive Officer Ron DiGiaimo. “Recognizing a need for a ‘best of the best’ is part of the company culture, and dictates everything Revenue Cycle does on a daily basis; the merger will increase our combination of resources and expertise.”

President of The Oncology Group Marsha Fountain adds, “The Oncology Group will continue its tradition of customized oncology services consulting and strategic planning for community and academic cancer centers. Our relationship with Revenue Cycle Inc., and their position as a key source of thought leadership within the physician practice arena increases both firms’ influence within an integrating cancer services market.”

The combined activities of both companies will continue The Oncology Group’s focus on all aspects of oncology growth and business management. Leaders from both merger partners agree that the strategic alliance will benefit their clients, as hospitals work to create and sustain integrated 21st century cancer centers and physician practices. For more information about Revenue Cycle Inc., please visit www.revenuecycleinc.com. To contact The Oncology Group visit www.theoncologygroup.com.

MUNDELEIN, IL–(Marketwire – August 10, 2010) –  ClearCount Medical Solutions and Medline Industries, Inc. today announced that their newest customers, the VA Pittsburgh Healthcare system, will help prevent retained surgical sponge incidents with the use of the SmartSponge System^®. The SmartSponge System is part of ClearCount’s radio-frequency identification (RFID)-based platform that uniquely identifies each sponge so that they can be easily counted and detected. Medline is the exclusive distributor for the SmartWand-DTX and the SmartSponge System, the only FDA-cleared systems using RFID to both count and locate surgical sponges.

“We are pleased to derive the benefits of such a comprehensive solution for the prevention of retained surgical sponges,” said Mark A. Wilson, M.D., Ph.D. Chief Surgeon and Medical Director of the Surgery Specialty Service Line, VA Pittsburgh. “We use the SmartSponge System to improve patient safety in our ORs with the goal of also improving efficiency. The uniqueness of this RFID platform is its integration of both counting and detection strategies. It is capable of growing with our patient safety initiatives, and we look forward to the future benefits it will provide.”

“The SmartSponge System provides a safety net for human error. Despite the level of experience of staff, individuals are bound to make mistakes. Distractions during counting and the mundane simplicity of ‘counting’ make the inevitability of losing track of a sponge a constant reality. The use of a system that virtually eliminates retained sponge incidents allows us to meet our ethical obligation to our patients,” said William Stevens, RN, BSN, CNOR Nurse Manager OR/PACU Surgery Specialty Service Line, VA Pittsburgh.

The VA Pittsburgh hospital has implemented SmartSponge Systems into its full suite of operating rooms. The national Veterans Health system, which includes 155 medical centers and 842 outpatient clinics, is the largest health care system in the US, with more than 5 million of the 25 million veterans alive today receiving its services.

“We’re pleased to add the VA Pittsburgh to our customer base,” said David Palmer, Chief Executive Officer of ClearCount. “The VA Pittsburgh has shown great leadership in terms of innovation and its commitment to patient safety. We are proud to now be a part of that continued tradition.”

Despite designation as a “never event,” retained items are estimated to occur in one of every 1,000 to 1,500 abdominal surgical procedures, which can lead to hospital inefficiencies, unnecessary costs, serious infections and even death. Hospital infections add an estimated $30.5 billion to the nation’s hospital costs each year. In one study using a retrospective review of medical malpractice claims data from a statewide insurer in Massachusetts, sponge counts had been falsely correct in 76 percent of non-vaginal surgical cases involving retained sponges. Falsely correct sponge counts were attributed to team fatigue, difficult or long operations, sponges “sticking together,” shift changes or procedures with a large number of sponges.

About ClearCount Medical Solutions
ClearCount Medical Solutions is a medical device company focused on patient safety solutions. ClearCount has assembled an extendable RFID-based platform that provides a comprehensive solution to improve efficiency while preventing medical errors, distributed exclusively by Medline. ClearCount Medical Solutions has been recognized with a Popular Science 2009 Best of What’s New Award, and has received additional recognition from TIME and WIRED magazines, the 2009 Wall Street Journal Technology Innovation Award, the International Design Excellence Award (IDEA) and more. ClearCount’s SmartSponge and SmartWand-DTX systems are the only RFID enabled systems for counting and detecting surgical sponges, thereby improving patient and OR safety, enhancing productivity, and reducing cost. To learn more, visit www.clearcount.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

ROCKVILLE, MD–(Marketwire – August 10, 2010) –  MarketResearch.com has announced the addition of Wintergreen Research’s new report “Long Term Care and Nursing Home Information Systems Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016” to their collection of Information Technology market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2746054

New long term care information systems have revolutionized the market, creating units that work across the board in long term care situations. This evolution of the software means that clinicians have more flexibility of care decisions, caring for people.

Information systems are emerging as a significant part of the nursing home and long term care delivery systems. All facilities have some kind of automated systems, but this study addresses the industry specific systems that are evolving with industry specific financial management and process integration. Software leverages the efficiency of clinical process in ways that have never become possible before. The electronic patient record can be integrated with financial systems, increasing the efficiency of transmitting services description to the insurance providers.

The ability to capture services delivery electronically at the point of care is central to creating more efficient infrastructure for the providers. The system leverages virtually all the administrative and financial information needed to run a successful home care company. Information can be gathered right from the charts.

The significance of integration systems is not yet realized in nursing home information systems. Collaboration and electronic patient records promise to drive the efficiencies gained from electronic records in to the clinical delivery process, giving caretakers more time to spend with patients. As patients move from one care venue to another, the patient record is going to need to move with them. The hand©held, computer-based system guides home care clinicians through the entire patient care process. Clinicians can use structured record guides. The systems automate reporting.

The fundamental aspect of long term care and nursing home information systems implementation relates to patient treatment flexibility. The ability to be responsive to changing patient conditions is central to the task of controlling nursing home and skilled nursing facility costs. The ability of systems to support flexibility in managing patients to lower cost care delivery sites is anticipated to spur rapid growth of the electronic patient record for these facilities. Long term care and nursing home information systems markets at $225.8 million in 2009 are anticipated to reach $674.9 million by 2016.

Topics covered in the report include…

• Nursing Home and Long Term Care Information Systems Market Description and Market Dynamics
• Long Term Care Information Systems
• Market Shares and Forecasts
• Long Term Care Information System Product Description
• Long Term Care Nursing Home Information Systems Technology
• Long Term Care Nursing Company Profiles

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2746054

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – Aug. 10, 2010) – DiaMedica Inc. (TSX VENTURE:DMA) today announced the appointment of Dr. Michael Giuffre to the company’s Board of Directors.

Dr. Giuffre is a Clinical Professor of Cardiac Sciences and Pediatrics at the University of Calgary. Dr Giuffre is currently a member on the board’s of the Alberta Medical Association and Unicef Canada. He is a past representative to the board of the Calgary Health Region and is an active participant in the biotechnology business sector.

“Dr. Giuffre’s clinical and business experience, particularly with his extensive cardiovascular background, will add additional depth to our Board,” stated Mr. Rick Pauls, President and CEO of DiaMedica.

“I am pleased to be joining the Board of Directors of DiaMedica at such a progressive time in its history,” stated Dr. Giuffre. “DiaMedica has very promising technology and I look forward to leveraging my experience as the company prepares for exciting and ambitious milestones.”

About Dr. Michael Giuffre

As a Clinical Professor of Cardiac Sciences and Pediatrics at the University of Calgary, Dr Giuffre maintains a portfolio of clinical practice, cardiovascular research, and university teaching. He maintains on-going involvement in both health care administration, and in the biotechnology business sector. Dr Giuffre is Past President of the Calgary and Area Physicians Association (CAPA) and a past representative to the board of the Calgary Health Region. Dr Giuffre holds a BSc in cellular and microbial biology, a PhD candidacy in molecular virology, an MD and an MBA. His Canadian Royal College board certified specialties include Pediatrics, Pediatric Cardiology and a subspecialty in Pediatric Electrophysiology.

As a biotechnology consultant, Dr. Giuffre has been involved with RedSky Inc. (acquired by Research in Motion), MDMI, and MedMira Inc. He is currently on the boards of IC2E Inc and FoodChek Inc. He serves on the Medical Advisory Board of the SADS Foundation and on the boards of Unicef Canada and the Alberta Medical Association. He is also an MD-MP contact for the Canadian Medical Association.

Dr Giuffre has recently received a Certified and Registered Appointment by the American Academy of Cardiology, “Distinguished Fellow of the American Academy of Cardiology,” and in 2005 was awarded “Physician of the Year” by the Calgary Medical Society.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders. The Company’s type 2 diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products, DM-71 and DM-99, have previously demonstrated human efficacy in lowering blood sugar levels in people diagnosed with type 2 diabetes based on this novel nerve signaling mechanism.

DiaMedica has expanded its DM-199 recombinant protein program into neurological and autoimmune disorders. The Company has demonstrated that DM-99, the naturally occurring form of DM-199, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”. For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the prospective Offering and the proceeds from the Offering, the anticipated use of proceeds from the Offering, regulatory approval of the Offering, and our other plans, estimates and expectations, including the completion of our proposed acquisition of Sanomune Inc. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our ability to complete the Offering, the availability of financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. 
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2008 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of financing for research and development companies, general business and economic conditions, and DiaMedica’s ability to complete its proposed acquisition of Sanomune Inc. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our proposed acquisition of Sanomune Inc. may be found in our press release dated February 18, 2010.

MENLO PARK, CA–(Marketwire – August 10, 2010) –  Allocade, Inc., the developer of healthcare’s most advanced tools to orchestrate patient flow, today announced the availability of new capabilities in its On-Cue® operations management software suite. On-Cue is powered by an artificial intelligence engine that orchestrates patient flow and automatically adapts to disruptions as they occur, enabling the industry’s only Dynamic Patient Itinerary™ — a time-tagged list of each patient’s preparation and procedure events that adapts in real-time as conditions change. This latest release from Allocade adds options to facilitate communications and manage operations while offloading logistical tasks from clinical staff.

The new capabilities for On-Cue were developed with input from customers. Key features include:

• An enterprise viewer, which allows access to the software suite from anywhere in the hospital, and from any device that is browser-enabled such as smart phones and tablets with access to the hospital’s network.
• Electronic protocoling that enables doctors, nurses and technologists to collaborate seamlessly, not only in preparation for procedures, but while they are actually in progress.
• A portable equipment component that manages the impacts to schedules when staff and equipment go portable in the hospital.

“Allocade continues in its tradition of constant innovation and adaptability with its latest software release,” said Joyce Lasich, Imaging System Administrator, Medical City Dallas Hospital. “We installed the enterprise viewer on all of our front desk computers and we can now ensure a higher quality of patient care and transparency throughout the hospital. We have the ability to view all patients’ imaging schedules with all of the pertinent information for the study with one interface. In addition, caregivers can now send and receive information about the current status of a patient with minimal disruption to workflow, which allows for more time with the patent.”

The immediate and positive response to the new capabilities from customers highlights Allocade’s ongoing commitment to developing software tools that provide powerful capabilities, while remaining simple to use.

Allocade’s Operations Management Software optimizes hospital patient flow for inpatients, outpatients and emergency patients. The software uses technology initially developed to manage workflow on the Hubble Space Telescope by Don Rosenthal, founder and chief technology officer of Allocade. The company’s patented Schedule Repair™ technology augments information already available in Hospital Information Systems (HIS), Radiology Information Systems (RIS) and Electronic Medical Record Systems (EMR) by adding layer of intelligence to these systems.

Allocade and On-Cue were prominently featured in the 2009 issue of NASA Spinoff; an annual book featuring successfully commercialized NASA technology. Allocade was also invited to participate in the May 2010 NASA Spinoff Day on the Hill, where it showcased On-Cue for members of Congress and NASA representatives.  

About Allocade
 Allocade, Inc. was founded in 2004 and is headquartered in Menlo Park, Calif. The company is a healthcare software company that develops tools to intelligently optimize patient flow throughout the hospital enterprise. Allocade’s first product is the On-Cue® Hospital Operations Management solution. The company’s management team includes former top executives from the NASA Ames Research Center, Siemens Medical Systems, Philips Medical Systems, Fujifilm Corporation, and Stentor. For more information, visit http://www.allocade.com.

On-Cue is a registered trademark, and Dynamic Patient Itinerary and Schedule Repair are trademarks of Allocade, Inc.

WEINHEIM, GERMANY–(Marketwire – August 10, 2010) – On July 23, 2010 the liver cell preparation by Cytonet GmbH & Co. KG received an Investigational New Drug allowance (IND) from the U.S. Food and Drug Administration (FDA). This is the first time a later stage clinical trial with liver cell therapy can now be started in the US. The FDA-approval is partly based on interim results of an ongoing clinical trial in Germany with neonatal patients suffering from urea cycle disorders (UCD). Cytonet will immediately start the clinical trial SELICA (Safety and Efficacy of Liver Cell Application)-III. The objective of this open, prospective, group-matched, historic-controlled multi-center study is to investigate the safety and efficacy of liver cell therapy in children suffering from UCD. Five therapy centers, as well as 10 centers actively assigning patients and responsible for the after-care, are participating in the SELICA-III trial. 

This study is the second clinical study on liver cell therapy in children suffering from UCD. The first trial, SELICA-II, has been running in Germany for approximately 1 year. SELICA-III comprises a six-month treatment and observation phase and a subsequent 18-month follow-up. The study includes infants, toddlers and children up to the age of five, who are suffering from the most severe forms of the following UCDs: ornithine transcarbamylase (OTC) deficiency, carbamoyl­phosphate synthetase I (CPS I) deficiency or argininosuccinate-synthetase (ASS) deficiency, also called citrullinemia. Cytonet would like to acknowledge the National Urea Cycle Disorders Foundation for its assistance during the development of the program. For more information about urea cycle disorders, visit the National Urea Cycle Disorders Foundation at www.nucdf.org.

About urea cycle disorders and liver cell therapy
UCDs are severe and life-threatening disorders of the ammonia (NH3) metabolism of the liver. These include carbamoylphosphate synthetase I (CPS) deficiency, N-acetylglu­tamate-synthetase (NAGS) deficiency, ornithine-transcarbamylase (OTC) deficiency, argininosuccinate-synthetase (ASS) deficiency — also known as citrullinemia, arginino­succinate-lyase (ASL) deficiency and arginase 1 deficiency (hyper­argi­ninemia). UCDs are based on disorders of 6 known enzymes that are involved in NH3-detoxification. In UCD-patients, the neurotoxic NH3 is not metabolized into urea and excreted. Instead, it accumulates in the blood and tissue. Depending on the severity of the disease, it leads to massive damage of the nerves and the brain, and can be fatal. Children who remain untreated rarely have a normal physical and mental development.

The only currently available cure is the transplantation of a whole liver or a liver lobe. However, this treatment is highly problematic for very young children and neonatal patients. Additionally, suitable organs available for transplantation are very rare. A therapy using isolated and processed liver cells from non-transplantable donated livers (manufactured under GMP standards) has been investigated and further developed over the past years. Cytonet is working in close cooperation with internationally leading neonatal and pediatric metabolism centers. The overall goal is an effective compensation of the metabolism disorder by means of the infusion of healthy, fully metabolism-competent human liver cells into the portal vein, subsequently engrafting in the liver of the child with the disorder.

About Cytonet
The Cytonet Group is an international biotechnology company with sites in Weinheim, Heidelberg and Hannover, Germany and Durham, NC, USA. Currently Cytonet has 60 employees. The company develops, produces and markets cell-therapeutic products for many diseases. In the process developed by Cytonet, liver cells from donated livers are gently isolated and cleaned up in a complex procedure. The donor livers, which are obtained from Organ Procurement Organizations in the United States, are unsuitable for organ transplantation. Additionally, Cytonet provides blood stem cell and bone marrow preparations for the therapy of leukemia and other malignant diseases. Managing directors are Dr. Wolfgang Rüdinger and Dipl.-Kfm. (MBA) Michael J. Deissner. Cytonet was founded by the demerger of the Cell Therapy department from the Roche Group in April 2000. The Dietmar Hopp family owns the majority of shares.

NEW YORK, NY and TORONTO–(Marketwire – August 10, 2010) –  A diverse marketing mix that includes and addresses communication preferences of readers is essential to any marketing or advertising campaign, and print marketing and direct mail still remain an integral part of that mix, says Patient News, a leading dental marketing solutions company.

“Statistics show that most marketers have found that online channels demonstrate greater value when distributed in conjunction with direct mail applications, reinforcing the value of print in the marketing mix,” said Karen Galley, President of Patient News.

Baby Boomers, who have an annual spending power of $2.1 trillion and account for upwards of 60% of all healthcare spending, actively shop through the mail and keep mail pieces for future reference. According to a research study by JWT BOOM and ThirdAge Inc., 90% of Baby Boomer women surveyed have seen a print ad and later visited the online site. As women make more than 85% of all healthcare buying decisions, this adds up to significant business that can be attributed to print marketing such as newsletters, direct mail or custom postcards.

In addition, the coveted 18-49 consumer group welcomes, reads and responds to printed materials. Close to 90% of this group sort through mail immediately, nearly 80% read direct mail advertising, and about 70% use coupons received in the mail.

“Print is an amazing online traffic generator, and it delivers consistent response rates,” said Galley. “People are more willing to try new brands than ever before, and those over 50 years old, the primary target for most of our dentists, are more likely than any other group to read and respond to direct mail pieces.”

For additional information on dental newsletters, variable data services, dental postcards, printed or e-dental advertising from Patient News call 800.667.0268 or visit www.Patientnews.com.

To read more on this topic, visit: http://www.patientnews.com/pressreleases/print-dental-marketing-in-mix.html.

About Patient News:

Patient News is North America’s most comprehensive and innovative provider of direct mail, newsletters, postcards, email newsletters, and referral cards. Founded in 1992, the company produces award-winning healthcare and dental marketing products in Canada, the United States, and the United Kingdom.

Click here to see all recent news from this company